Author: "François Paillard" - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"François Paillard"' showing total 85 results

Start Over Author "François Paillard"

85 results on '"François Paillard"'

1. A retrospective analysis on optimal medical therapy for patients with symptomatic lower extremity peripheral artery disease: a French observational study

Author: Camille de Kermenguy, Anne Durand, Quentin Tollenaere, Estelle Le Pabic, François Paillard, and Guillaume Mahé
Subjects: Peripheral artery disease, Treatment, Lipid objectives, Triglycerides, Diseases of the circulatory (Cardiovascular) system, RC666-701
Abstract: Abstract Objective Patients with symptomatic lower extremity artery disease (LEAD) should have an optimal management in terms of lipid goal [i.e. controlled LDL-cholesterol (LDLc)] and medical treatment (triple therapy with an antiplatelet agent, a statin and an angiotensin-converting enzyme inhibitor or a angiotensin-receptor antagonist). Prevalence of LEAD patients with a LDLc
Published: 2024
Full Text: View/download PDF

2. Burden of cardiovascular disease in a large contemporary cohort of patients with heterozygous familial hypercholesterolemia

Author: Jean Ferrières, Michel Farnier, Eric Bruckert, Alexandre Vimont, Vincent Durlach, Emile Ferrari, Antonio Gallo, Franck Boccara, Dorota Ferrières, Sophie Béliard, Denis Angoulvant, Karine Aouchiche, Sophie Beliard, Bertrand Cariou, Valérie Carreau, Alain Carrie, Sybil Charrieres, Yves Cottin, Mathilde Di Filippo, Caroline Dourmap, Pierre-Henri Ducluzeau, Dorota Ferrieres, Jean Ferrieres, Regis Hankard, Jocelyn Inamo, Olga Kalmykova, Michel Krempf, Julie Lemale, Philippe Moulin, François Paillard, Noel Peretti, Agnes Perrin, Alain Pradignac, Yann Pucheu, Jean Pierre Rabes, Rachel Reynaud, Vincent Rigalleau, François Schiele, Ariane Sultan, Patrick Tounian, René Valero, Bruno Verges, Cecile Yelnik, and Olivier Ziegler
Subjects: Heterozygous familial hypercholesterolemia, Registry, Incidence, Recurrence, Lipid-lowering treatment, Prognosis, Diseases of the circulatory (Cardiovascular) system, RC666-701
Abstract: Background and aims: Heterozygous familial hypercholesterolemia (HeFH) is increasingly better diagnosed and treatments can improve the cardiovascular prognosis. We evaluated the long-term cardiovascular risk of HeFH using the French REgistry of Familial hypERCHOLesterolemia (REFERCHOL). Methods: We studied HeFH patients diagnosed genetically and clinically by the Dutch Lipid Clinic Network (DLCN) criteria in all lipid clinics across the country and their 5-year risk of cardiovascular events (all fatal and non-fatal acute coronary, cerebral and peripheral arterial disease events, aortic valve replacement surgery) using the French national health data system. Results: The database comprised 3202 individuals, 2010 (62.8%) with genetically verified HeFH and 1192 (37.2%) a DLCN score ≥6. Of these individuals, 2485 (77.6%) were in primary prevention and 717 (22.4%) in secondary prevention. The incidence of cardiovascular events was 24.58 per 1000 person-years for the overall sample, 19.15 in primary prevention and 43.40 in secondary prevention. The incidence of myocardial infarction, cerebral infarction and death was 16.32 per 1000 person-years for the overall sample, 12.93 in primary prevention and 28.08 in secondary prevention. The incidence of aortic valve replacement was 1.78 per 1000 person-years. In the overall sample, at inclusion, 41% were not treated for LDL cholesterol, 48% of these in primary prevention and 20% in secondary prevention and high-dose statins were used by only 24% of individuals, 15% of these in primary prevention and 45% in secondary prevention. Conclusions: The incidence of cardiovascular events in HeFH is high and lipid-lowering treatment is far from optimal. The cardiovascular risk of HeFH is underestimated and patients are inadequately treated.
Published: 2022
Full Text: View/download PDF

3. Impact of dietary intervention on eating behavior after ischemic stroke

Author: Samuel Besseau, Eric Sartori, Pauline Larnier, François Paillard, Bruno Laviolle, and Guillaume Mahé
Subjects: diet, dietary consultation, ischemic stroke, nutrition, questionnaire, Nutrition. Foods and food supply, TX341-641
Abstract: ObjectiveIschemic stroke is a major health issue. Currently, the relationship between dietary patterns and the occurrence of cardiovascular diseases including stroke is established, but the effect of systematic dietary intervention on dietary changes in ischemic stroke patients is unknown. Our objective was to compare changes in the dietary pattern of ischemic stroke patients who received a systematic diet intervention with changes in the dietary pattern of ischemic stroke patients who did not receive a systematic dietary intervention during their hospitalization.MethodsIn this before-and-after study, two groups of patients with ischemic stroke were compared: Group 1 included 34 patients admitted with an ischemic stroke without a systematic dietray intervention; Group 2 included 34 patients admitted with an ischemic stroke with a systematic dietary intervention. Dietary patterns were assessed by a validated food frequency questionnaire of 19 questions (from a previously validated questionnaire of 14 questions), at the onset of stroke and at 6 months after stroke. This questionnaire allows the calculation of different scores as follows: global food score, saturated fatty acids score (SFA), unsaturated fatty acids score (UFA), fruit and vegetable score, and alcohol score.ResultsScore changes were more important in group 2 than in group 1 for the global food score (7.4 ± 7 vs. 1.9 ± 6.7, p = 0.0013), the fruit and vegetable score (2 ± 2.6 vs. 0.6 ± 2.2, p = 0.0047), and the UFA score (1.8 ± 2.7 vs. 0.1 ± 3.3, p = 0.0238), whereas no significant differences were observed for the SFA score (−3.9 ± 4.9 vs. −1.6 ± 6, p = 0.1779) and the alcohol score (−0.4 ± 1.5 vs. −0.3 ± 1.1, p = 0.6960).ConclusionThis study showed that systematic dietary intervention during hospitalization improves the dietary patterns of ischemic stroke patients. The impact on the recurrence of ischemic stroke or cardiovascular events after dietary pattern changes needs to be studied.
Published: 2023
Full Text: View/download PDF

4. Effectiveness of angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers on total and cardiovascular mortality and morbidity in primary prevention: A nationwide study based on French Health Insurance Data (SNDS)

Author: Emmanuel Oger, Sandrine Kerbrat, Emmanuel Nowak, François Paillard, Pierre‐Yves Scarabin, and André Happe
Subjects: angiotensin receptor blockers, angiotensin‐converting enzyme inhibitors, cardiovascular diseases, mortality, Diseases of the circulatory (Cardiovascular) system, RC666-701
Abstract: Abstract Angiotensin‐converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) both inhibit the renin‐angiotensin system (RAS) but have different sites of action. Whether clinically meaningful differences exist is still debated. The authors set up a population‐based nationwide retrospective cohort study with at least 5 years of follow‐up based on the comprehensive French Health Insurance Database linked to the French hospital discharge database. Patients aged 50 or above, identified as ARB or ACE inhibitor new users in 2009 (at least one delivery during the year and no such delivery in 2008) were eligible. Exclusion criteria included history of cancer, cardiovascular disease, or chronic renal insufficiency. Main outcome measure was overall mortality. Secondary outcomes were cardiovascular deaths, major cardiovascular events, and major or other cardiovascular events. Out of 407 815 eligible patients, 233 682 (57%) were ARB users; two‐third had no previous exposure to antihypertensive drug. Based on propensity‐score based Cox model, ARB new user group had a better overall (HR: .878, 95%CI, .854 to .902), and cardiovascular (HR: .841, 95%CI, .800 to .84) survival and had a lower risk for major cardiovascular events (HR: .886, 95%CI, .868 to .905). Statistically significant quantitative interactions were detected with diabetes. Considering subgroup analyses, ARBs had a better survival than ACE inhibitors in nondiabetic patients.
Published: 2022
Full Text: View/download PDF

5. Additive Effect of APOE Rare Variants on the Phenotype of Familial Hypercholesterolemia

Author: Oriane Marmontel, Yara Abou-Khalil, Olivier Bluteau, Bertrand Cariou, Valérie Carreau, Sybil Charrière, Eleonore Divry, Antonio Gallo, Philippe Moulin, François Paillard, Noel Peretti, Jean-Pierre Rabès, Mathilde Varret, Alain Carrié, and Mathilde Di Filippo
Subjects: Cardiology and Cardiovascular Medicine
Abstract: Background: Autosomal dominant hypercholesterolemia (ADH) is due to deleterious variants in LDLR , APOB , or PCSK9 genes. Double heterozygote for these genes induces a more severe phenotype. More recently, a new causative variant of heterozygous ADH was identified in APOE . Here we study the phenotype of 21 adult patients, double heterozygotes for rare LDLR and rare APOE variants ( LDLR+APOE ) in a national wide French cohort. Methods: LDLR , APOB , PCSK9 , and APOE genes were sequenced in 5743 probands addressed for ADH genotyping. The lipid profile and occurrence of premature atherosclerotic cardiovascular diseases were compared between the LDLR+APOE carriers (n=21) and the carriers of the same LDLR causative variants alone (n=22). Results: The prevalence of LDLR+APOE carriers in this French ADH cohort is 0.4%. Overall, LDL (low-density lipoprotein)-cholesterol concentrations were 23% higher in LDLR+APOE patients than in LDLR patients (9.14±2.51 versus 7.43±1.59 mmol/L, P=0 .0221). When only deleterious or probably deleterious variants were considered, the LDL-cholesterol concentrations were 46% higher in LDLR+APOE carriers than in LDLR carriers (10.83±3.45 versus 7.43±1.59 mmol/L, P=0 .0270). Two patients exhibited a homozygous familial hypercholesterolemia phenotype (LDL-cholesterol >13 mmol/L). Premature atherosclerotic cardiovascular disease was more common in LDLR+APOE patients than in LDLR carriers (70% versus 30%, P=0 .026). Conclusions: Although an incomplete penetrance should be taken into account for APOE variant classification, these results suggest an additive effect of deleterious APOE variants on ADH phenotype highlighting the relevance of APOE sequencing.
Published: 2023
Full Text: View/download PDF

6. Maternal Inheritance of Familial Hypercholesterolemia Gene Mutation Predisposes to Coronary Atherosclerosis as Assessed by Calcium Score in Adulthood

Author: Florian Mourre, Roch Giorgi, Antonio Gallo, Franck Boccara, Eric Bruckert, Alain Carrié, Regis Hankard, Jocelyn Inamo, Sandrine Laboureau, Philippe Moulin, René Valéro, Sophie Béliard, Denis Angoulvant, Sophie Beliard, Bertrand Cariou, Valérie Carreau, Alain Carrie, Sybil Charrieres, Yves Cottin, Mathilde Di Filippo, Pierre Henri Ducluzeau, Sonia Dulong, Vincent Durlach, Michel Farnier, Emile Ferrari, Dorota Ferrieres, Jean Ferrieres, Olga Kalmykova, Michel Krempf, Julie Lemale, François Paillard, Noel Peretti, Agnes Perrin, Alain Pradignac, Jean Pierre Rabes, Vincent Rigalleau, François Schiele, Ariane Sultan, Patrick Tounian, René Valero, Bruno Verges, Cecile Yelnik, Olivier Ziegler, Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] (IHU ICAN), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Nutrition, croissance et cancer (U 1069) (N2C), Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (C2VN), and Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)
Subjects: [SDV]Life Sciences [q-bio], hyperlipidemia, maternal inheritance, risk factors, atherosclerosis, Cardiology and Cardiovascular Medicine, cardiovascular diseases
Abstract: Background: Animal studies have demonstrated that fetal exposure to high maternal cholesterol levels during pregnancy predisposes to aortic atheroma in the offspring. In humans, little is known about the consequences of this exposure on the development of atherosclerotic cardiovascular disease later in life. We wanted to assess whether maternal/paternal inheritance of familial hypercholesterolemia (FH) gene mutation could be associated with subclinical coronary atherosclerosis. Methods: We retrospectively included 1350 patients, followed in the French registry of FH, with a documented genetic diagnosis. We selected 556 age- and sex-matched pair of patients based on the sex of the parents who transmitted the FH gene mutation, free of coronary cardiovascular event, and with a subclinical coronary atherosclerosis evaluation assessed using coronary artery calcium (CAC) score. We performed univariate and multivariate analysis to assess the individual effect of parental inheritance of the FH gene mutation on the CAC score. Results: In the whole population, patients with maternal inheritance of FH gene mutation (n=639) less frequently had a family history of premature cardiovascular events (27.7% versus 45%, P P =0.02) than those with paternal inheritance (n=711). There was no difference in the prevalence of cardiovascular events between the two groups. In the matched subgroup, maternal inheritance was significantly associated with an increase in CAC score value by 86% (95% CI, 23%–170%; P =0.003), a 1.81-fold risk of having a CAC score ≥100 Agatston units (95% CI, 1.06–3.11; P =0.03), and a 2.72-fold risk of having a CAC score ≥400 Agatston units (95% CI, 1.39–5.51; P =0.004) when compared with paternal inheritance in multivariate analysis. Conclusions: Maternal inheritance of FH gene mutation was associated with more severe subclinical coronary atherosclerosis assessed by CAC score and may be considered as a potential cardiovascular risk factor.
Published: 2023
Full Text: View/download PDF

7. The Added Value of Coronary Calcium Score in Predicting Cardiovascular Events in Familial Hypercholesterolemia

Author: Antonio Gallo, Leopoldo Pérez de Isla, Sybil Charrière, Alexandre Vimont, Rodrigo Alonso, Ovidio Muñiz-Grijalvo, José L. Díaz-Díaz, Daniel Zambón, Philippe Moulin, Eric Bruckert, Pedro Mata, Sophie Béliard, Denis Angoulvant, Sophie Beliard, Franck Boccara, Bertrand Cariou, Valérie Carreau, Alain Carrie, Sybil Charrieres, Yves Cottin, Mathilde Di Filippo, Pierre Henri Ducluzeau, Sonia Dulong, Vincent Durlach, Michel Farnier, Emile Ferrari, Dorota Ferrieres, Jean Ferrieres, Philippe Giral, Sophie Gonbert, Regis Hankard, Jocelyn Inamo, Olga Kalmykova, Michel Krempf, Julie Lemale, François Paillard, Noel Peretti, Agnes Perrin, Alain Pradignac, Jean Pierre Rabes, Vincent Rigalleau, François Schiele, Ariane Sultan, Patrick Tounian, René Valero, Bruno Verges, Cecile Yelnik, Olivier Ziegler, Rocío Aguado, Ma Pilar Álvarez-Baños, Rosa Argüeso, Francisco Arrieta, Miguel Ángel Barba, Marta Casañas, José María Cepeda, Raimundo De Andrés, Gonzalo Díaz-Soto, Jose Luis Díaz-Diaz, Marta Dieguez, Ceferino Faedo, Francisco Fuentes, Juan A. Garrido, Aurora González, Pablo González-Bustos, Ma Dolores Mañas, Marta Mauri, Juan Diego Mediavilla, Alfredo Michán, Pablo Miramontes, Ovidio Muñiz, Leire Pérez, Leopoldo Perez De Isla, Xavier Pintó, Manuel J. Romero, Patricia Rubio, Juan F. Sánchez Muñoz-Torrero, Jose I. Vidal-Pardo, Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] (PhyMedExp), Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Laboratoire d'Imagerie Biomédicale (LIB), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Instituto de Investigación Sanitaria del Hospital Clínico San Carlos [Madrid, Spain] (IdISSC), Universidad Complutense de Madrid = Complutense University of Madrid [Madrid] (UCM), Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Public Health Expertise [Paris, France], Hospital Universitario Virgen del Rocío [Sevilla], Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona (UB), Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (C2VN), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Hôpital de la Conception [CHU - APHM] (LA CONCEPTION), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Laboratoire d'Imagerie Biomédicale [Paris] (LIB), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] (IHU ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Pitié-Salpêtrière [AP-HP], Hospital Abente y Lago, Fundación Hipercolesterolemia Familiar, and ANR-16-RHUS-0007,CHOPIN,CHOPIN(2016)
Subjects: Adult, Male, medicine.medical_specialty, [SDV]Life Sciences [q-bio], Coronary Artery Disease, Disease, Familial hypercholesterolemia, 030204 cardiovascular system & hematology, Risk Assessment, Sudden death, Cohort Studies, Hyperlipoproteinemia Type II, risk prediction, 03 medical and health sciences, 0302 clinical medicine, cardiovascular disease, genetic disease, Predictive Value of Tests, Risk Factors, Interquartile range, Internal medicine, Humans, Medicine, Radiology, Nuclear Medicine and imaging, 030212 general & internal medicine, Vascular Calcification, Stroke, coronary artery calcium, ComputingMilieux_MISCELLANEOUS, familial hypercholesterolemia, business.industry, Proportional hazards model, nutritional and metabolic diseases, Middle Aged, Atherosclerosis, medicine.disease, 3. Good health, Coronary Calcium Score, Cardiology, Calcium, Cardiology and Cardiovascular Medicine, business, coronary imaging, Cohort study
Abstract: International audience; ObjectivesThis study aimed at investigating the additional contribution of coronary artery calcium (CAC) score to SAFEHEART (Spanish Familial Hypercholesterolemia Cohort Study) risk equation (SAFEHEART-RE) for cardiovascular risk prediction in heterozygous familial hypercholesterolemia (HeFH).BackgroundCommon cardiovascular risk equations are imprecise for HeFH. Because of the high phenotype variability of HeFH, CAC score could help to better stratify the risk of atherosclerotic cardiovascular disease (ASCVD).MethodsREFERCHOL (French Registry of Familial Hypercholesterolemia) and SAFEHEART are 2 ongoing national registries on HeFH. We analyzed data from primary prevention HeFH patients undergoing CAC quantification. We used probability-weighted Cox proportional hazards models to estimate HRs. Area under the receiver-operating characteristic curve (AUC) and net reclassification improvement (NRI) were used to compare the incremental contribution of CAC score when added to the SAFEHEART-RE for ASCVD prediction. ASCVD was defined as coronary heart disease, stroke or transient ischemic attack, peripheral artery disease, resuscitated sudden death, and cardiovascular death.ResultsWe included 1,624 patients (mean age: 48.5 ± 12.8 years; men: 45.7%) from both registries. After a median follow-up of 2.7 years (interquartile range: 0.4-5.0 years), ASCVD occurred in 81 subjects. The presence of a CAC score of >100 was associated with an HR of 32.05 (95% CI: 10.08-101.94) of developing ASCVD as compared to a CAC score of 0. Receiving-operating curve analysis showed a good performance of CAC score alone in ASCVD prediction (AUC: 0.860 [95% CI: 0.853-0.869]). The addition of log(CAC + 1) to SAFEHEART-RE resulted in a significantly improved prediction of ASCVD (AUC: 0.884 [95% CI: 0.871-0.894] for SAFEHEART-RE + log(CAC + 1) vs AUC: 0.793 [95% CI: 0.779-0.818] for SAFEHEART-RE; P < 0.001). These results were confirmed also when considering only hard cardiovascular endpoints. The addition of CAC score was associated with an estimated overall net reclassification improvement of 45.4%.ConclusionsCAC score proved its use in improving cardiovascular risk stratification and ASCVD prediction in statin-treated HeFH.
Published: 2021
Full Text: View/download PDF

8. Evaluation of lipoprotein(a) in the prevention and management of atherosclerotic cardiovascular disease: A survey among the Lipid Clinics Network

Author: Catapano, Alberico L, Tokgözoğlu, Lale, Banach, Maciej, Gazzotti, Marta, Olmastroni, Elena, Casula, Manuela, Ray, Kausik K, the Lipid Clinics Network, Alaa ABDELRAZIK (University Hospital of North Midland, United Kingdom), Alberto MELLO E SILVA (Sociedade Portuguesa de Aterosclerose, Portugal), Alexander VONBANK (VIVIT Institute, Austria), Alexandros, D TSELEPIS (Dept of Chemistry, Atherothrombosis Research Center, University of Ioannina, Greece), Alper SONMEZ (Department of Endocrinology and Metabolism, Ankara Guven Hospital, Turkey), Angelina PASSARO (Department of Translational Medicine, University of Ferrara &amp, Center for the Study and Treatment of Metabolic Diseases, Atherosclerosis, and Clinical Nutrition, University Hospital of Ferrara Arcispedale Sant’Anna, Italy), Anja VOGT (Medizinische Klinik und Poliklinik IV, Klinikum der Universit¨at München, Germany), Ann MERTENS (Clinical and Experimental Endocrinology, Leuven, Ku, Leuven, Belgium), Ann VERHAEGEN (Antwerp University Hospital, Belgium), Arman, S POSTADZHIYAN (Medical University of Sofia, Saint Anna University Hospital, Departement of Cardiology, Bulgaria), BAHADIR KIRILMAZ (Canakkale Onsekiz Mart University, Medical Faculty Cardiology Dept, Baris GUNGOR (University of Health Sciences Dr. Siyami Ersek Hospital, Turkey), Berit S HEDEGAARD (Aalborg University, Denmark), Bertrand CARIOU (Nantes Universit´e, Chu, Nantes, Cnrs, Inserm, l’institut du thorax, Nantes, France), Britta OTTE (Universit¨atsklinikum Münster, Lipidambulanz, Germany), Bu˘gra ¨OZKAN (Mersin University, Turkey), of cardiology, Christ BERGE (Dept., Unversity Hopsital, Haukeland., Norway), F EBENBICHLER (Department for Internal Medicine I, Christoph, Medical University Innsbruck, Austria), Christoph J BINDER (Medical University of Vienna, Austria), Christoph OLIVIER (Department of Cardiology and Angiology, University Heart Center Freiburg-Bad Krozingen, Faculty of Medicine, University of Freiburg, Conrad AZZOPARDI (Mater Dei Hospital, Malta), Cristina SOLER (Lipid Unit, Hospital de Sta Caterina, Spain), Dan GAITA (Universitatea de Medicina si Farmacie Victor Babes din Timisoara &amp, Clinica de Cardiologie, Institutul de Boli Cardiovasculare Timisoara, Romania), Daniel WEGHUBER (Department of Pediatrics, Paracelsus Medical University, Dilek URAL (Koç University School of Medicine Department of Cardiology, Turkey), Diogo CRUZ (Hospital de Cascais - Dr. Jos´e de Almeida, Portugal), Dragos VINEREANU (University of Medicine and Pharmacy, University and Emergency Hospital, Bucharest, Romania), Elena D PENCU (Grand Hˆopital de Charleroi GHDC, Belgium), Emil HAGSTR¨OM (Dept of medical sciences, Uppsala, University, Sweden), Erik B SCHMIDT (Aalborg University, Denmark), Erik, S STROES (Dept of vascular medicine, Amsterdamumc, The, Netherlands), Evangelos LIBEROPOULOS (1st Department of Propedeutic Medicine, School of Medicine, National and Kapodistrian University of Athens, General Hospital of Athens Laiko, Fabian DEMEURE (CHU UCL Namur - Site Godinne, Belgium), Fabio FIMIANI (Azienda Ospedaliera di Rilievo Nazionale AORN Dei Colli, Monaldi', 'V., Unit of Inherited and Rare Cardiovascular Diseases, Italy, ), Fabio PELLEGATTA (Center for the Study of Atherosclerosis. Bassini Hospital. Cinisello Balsamo, Italy), Fahri BAYRAM (Erciyes University, Turkey), Finn L HENRIKSEN (Department of Cardiology Odense University Hospital, Denmark), Florian H¨OLLERL (1st Medical Department, Landstrasse, Clinic, Vienna Health Association, Francesco CIPOLLONE (Clinica Medica Institute of, Department of Medicine and Aging Sciences, d’Annunzio' University, 'G., Francisco ARAÚJO (Hospital Lusíadas, Portugal), Franck BOCCARA (Sorbonne Universit´e, Groupe de Recherche Clinique number 22, C2MV—Complications Cardiovasculaires et M´etaboliques chez les Patients Vivant avec le Virus de l’Immunod´eficience Humaine, Institut National de la Sant´e et de la Recherche M´edicale Unit´e Mixte de Recherche, S 938, Centre de Recherche Saint-Antoine, Institut Hospital Universitaire de Cardiom ´etabolisme et Nutrition Cardiologie, Hˆopital Saint Antoine Assistance Publique–Hˆopitaux de Paris, Paris, France), François PAILLARD (Cardiologie et Centre Clinico-Biologique des Lipides et Ath´eroscl´erose, Chu, Rennes, France), Imre University Teaching Hospital, Gabor SIMONYI (DBC St., Metabolic, Center, Lipid, Center, Hungary), Gabriella IANNUZZO (Department of Clinical Medicine and Surgery. University of Naples Federico II, Italy), Giuseppe MANDRAFFINO (Department of Clinical and Experimental Medicine, - Lipid Center, University of Messina, Graham BAYLY (Dept Clinical Biochemistry, University Hospitals Bristol, United, Kingdom), Gustavs LATKOVSKIS (Institute of Cardiology and Regenerative Medicine, University of Latvia &amp, Latvian Center of Cardiology, Pauls Stradins Clinical University Hospital &amp, University of Latvia, Latvia), Gy¨orgy PARAGH (Division of Metabolic Disorders, Department of Internal Medicine, University of Debrecen, Debrecen, Hungary), Hana ROSOLOVA (Charles University Prague Medical Hospital in Pilsen, Czech Republic), Handrean SORAN (Central Manchester University Hospital NHS Foundation Trust, United Kingdom), Helle KANSTRUP (Department of cardiology, Aarhus University hospital, Denmark), Hermann TOPLAK (Department of Medicine, Division of Endocrinology and Diabetology, Medical University Graz, Hülya ÇIÇEKÇIO ˘GLU (ankara bilkent city hospital, Turkey), Inanc ARTAC (Department of Cardiology, Kafkas University Hospital, Ioanna GOUNI-BERTHOLD (Center for Endocrinology, Diabetes and Preventive Medicine, University of Cologne, Faculty of Medicine and University Hospital Cologne, Irfan, V DUZEN (Gaziantep University, Cardiology, Department, Isabel M PALMA (CHUPORTO - Centro Hospitalar Universit ´ario do Porto, Portugal), Istvan REIBER (Szent Gyorgy University Teaching Hospital of Fejer County, Hungary), Iveta DZIVITE-KRISANE (Children’s University Hospital, Latvia), Jeanine, E ROETERS VAN LENNEP (Department of Internal medicine, Erasmus MC University Medical Center, Jean-Luc, J BALLIGAND (Institut de Recherche Exp´erimentale et Clinique, Universite catholique de Louvain, Bruxelles), Joao C PORTO (CHUC, Portugal), Jo˜ao, S DUARTE (Hospital Egas Moniz, Lisboa, Portugal), Johan DE SUTTER (AZ Maria Middelares Hospital Gent, Belgium), Jos´e L´OPEZ-MIRANDA (Lipid and Arteriosclerosis Unit. Department of Internal Medicine. Hospital Universitario Reina Sofia. IMIBIC. University of Cordoba. CiberOBN, Spain), Jose M MOSTAZA (Hospital La Paz-Carlos III, Spain), Jurgita PLISIENE (Lithuanian University of Health sciences, Lithuania), Kadir, U MERT (Eskis ¸ehir Osmangazi University, Department of Cardiology, Kirsten, B HOLVEN (Department of Nutrition, University of Oslo and National Advisory unit on FH, Oslo University Hospital, Kjetil RETTERSTØL (The Lipid Clinic, Oslo University Hospital and Department of Nutrition, University of Oslo, Kristian, K THOMSEN (University Hospital of South Denmark, Esbjerg, Denmark), Lale TOKGOZOGLU (Hacettepe University, Turkey), Laszlo BAJNOK (1st Department of Medicine, Medical, School, University of Pecs, Lia E BANG (Copenhagen University Hospital, Denmark), Liliana GRIGORE (IRCCS Multimedica, Italy), Lluís MASANA (Hospital Universitari Sant Joan. Universitat Rovira i Virgili. CIBERDEM. Reus, Spain), Loukianos S RALLIDIS (University General Hospital Attikon, Greece), Maciej BANACH (Department of Preventive Cardiology and Lipidology, Medical University of Lodz, Poland), Małgorzata WALU´S-MIARKA (Jagiellonian University Medical College, Of Metabolic Diseases and Diabetology, Dept., Manuel CASTRO CABEZAS (Franciscus Gasthuis &amp, Vlietland Rotterdam, The Netherlands), Marcello ARCA (Sapienza University of Rome, Italy), Margus VIIGIMAA (North Estonia Medical Centre, Tallinn University of Technology, Estonia), Martin, P BOGSRUD (Unit for Cardiac and Cardiovascular Genetics, Matej MLINARIˇC (Department of Endocrinology, Diabetes and Metabolism, University Children’s Hospital, University Medical Centre Ljubljana, Slovenia), Matteo PIRRO (Section of Internal Medicine, Angiology and Arteriosclerosis Diseases, Maurizio AVERNA (Department PROMISE-University of Palermo &amp, Istituto di Biofisica, Consiglio Nazionale delle Ricerche, Palermo, Italy), Meral KAYIKCIOGLU (Ege University Medical School Department of Cardiology, Turkey), Merete HEITMANN (Bispebjerg-Frederiksberg University Hospital, Denmark), Mette MOURIDSEN (Department of Cardiology, Herlev and Gentofte Hospital, University of Copenhagen, Michal VRABLIK (3rd Department of Internal Medicine, General University Hospital and 1st Medical Faculty, Charles, University, Prague, Czech, Republic), Michel FARNIER (PEC2, University of Bourgogne Franche-Comt´e, Laboratory Medicine, Michel R LANGLOIS (Dept., Jan Hospital, AZ St., Belgium), Milad KHEDR (Department of Clinical Biochemistry and Metabolic Medicine, Royal Liverpool University Hospital, Muge ILDIZLI DEMIRBAS (Kartal Kosuyolu Research and Training Hospital, Turkey), Myra TILNEY (Lipid Clinic, Mater Dei Hospital &amp, Dept of Medicine, University of Malta Medical School, Malta), Nadia CITRONI (Internal Medicine, APSS Trento Hospital, Of Internal Medicine, Niels P RIKSEN (Dept., Radboud university medical center, Nikolay M RUNEV (UMHAT Alexandrovska, Bulgaria), Nora KUPSTYTEKRISTAPONE (Hospital of Lithuanian University of Health Sciences Kaunas Clinics, Lithuania), Olena MITCHENKO (NSC, Clinical and Regenerative Medicine of the NAMS of Ukraine, Ukraine), Oliver WEING¨ARTNER (Universit¨atsklinikum Jena, Department of Internal Medicine, I, Oner OZDOGAN (University of Health Sciences, Izmir Faculty of Medicine, Tepecik Training and Research Hospital, Ovidio MU˜NIZGRIJALVO (Hospital Virgen del Rocío, Spain), Ozcan BASARAN (Mugla Sitki Kocman University, Pankaj GUPTA (University Hospitals of Leicester, United Kingdom), Paolo PARINI (Cardio Metabolic Unit, Karolinska, Institutet, and Theme Inflammation and Ageing, Karolinska University Hospital Huddinge, Patrizia SUPPRESSA (Department of Internal Medicine and rare disease Centre, Bari, Italy), Paul DOWNIE (Salisbury NHS Foundation trust, United Kingdom), Pavel JESINA (Metabolic Center General University Hospital, Czech Republic), of Internal Medicine, Pavel KRAML (Dept., Third Faculty of Medicine, Charles University and Kr´alovsk´e Vinohrady University Hospital Prague, Pawel BURCHARDT (Department of Cardiology, Cardiovascular, Unit, Hospital, J. Stru´s., Pozna´n, &amp, Department of Hypertension, Angiology and Internal Medicine, Poznan University of Medical Sciences, Pozna´n, Poland), Pedro VALDIVIELSO (Hospital VIRGEN DE LA VICTORIA, Spain), Pedro VON HAFE (Instituto Cuf, Portugal), Dept, Peter FASCHING (5th Med., Clinic, Ottakring, Philippe MOULIN (Hospices civils de Lyon/INSERM/Universit ´e Lyon1, Hˆopital Louis Pradel, F´ed´eration, D’Endocrinologie, Quit´eria RATO (Sociedade Portuguesa de Aterosclerose, Portugal), Reinhold INNERHOFER (Medical University Vienna, Austria), Renata C´IFKOV´A (Center for Cardiovascular Prevention, Charles University in Prague, First Faculty of Medicine and Thomayer University Hospital, Rene VALERO (Aix Marseille Univ, Aphm, Inserm, Inrae, C2vn, University Hospital La Conception, Department of Nutrition, Metabolic Diseases and Endocrinology, Scicali, Roberto, Robin URB´ANEK (Internal medicine, Obezita-Ormiga, s. r. o., Roma KAVALIAUSKIENE (Klaip˙ eda Seamen’s Hospital, Lituania), Roman CIBULKA (Department of paramedic science, medical diagnostics studies and public health, Faculty of Health Care Studies, University of West Bohemia, Sabina ZAMBON (Department of Medicine, - DIMED, University of Padova, Sergio D’ADDATO (University of Bologna. IRCCS S. Orsola Bologna, Italy), Stanislav ZEMEK (Lipidova ambulance, Czech Republic), Stefano ROMEO (Gothenburg University, Sweden), Stephanie K¨ONEMANN (Department of Internal Medicine, B, University Medicine Greifswald, DZHK (German Centre for Cardiovascular Research), Susanne GREBER-PLATZER (Clinical Division of Pediatric Pulmonology, Allergology and Endocrinology, Department of Pediatrics and Adolescent Medicine, Medical University Vienna, Thomas STULNIG (Clinical Division of Endocrinology and Metabolism, Department of Medicine III, Medical University Vienna &amp, Third Medical Department and Karl Landsteiner Institute for Metabolic Diseases and Nephrology, Clinic, Hietzing, Vienna, Austria), Thomas MUHR (Dept of Cardiology, Link¨oping University Hospital, Tina, Z KHAN (Consultant Cardiologist, Royal Brompton and Harefield Hospitals Part of Guy’s and St Thomas’ NHS Foundation Trust, Tomas FREIBERGER (Centre of Cardiovascular Surgery and Transplantation, Brno &amp, Medical, Faculty, Masaryk, University, Brno, Tom´aˇs ˇS´ALEK (Metabolic Clinic, Tomas Bata Hospital, Zlín, Tomas VASYLIUS (Republican Panevezys hospital, Of Cardiology, Dep., Lithuania), Ulrich LAUFS (Klinik und Poliklinik für Kardiologie, Universit ¨atsklinikum Leipzig, Ulrike SCHATZ (University Hospital Carl Gustav Carus Dresden at the Technical University Dresden, Department of Internal Medicine III, Urh GROSELJ (UMC, - University Children’s Hospital Ljubljana, University of Ljubljana, Victoria MARCO-BENEDI (Hospital Universitario Miguel Servet, Iisa, Cibercv, Vincent MAHER (Advanced Lipid Management and Research ALMAR centre, Tallaght University Hospital, Ireland), Vladimír BLAHA (University Hospital Hradec Kr´alov´e and Charles University, Faculty of Medicine in Hradec Kr´alov´e, 3rd Department of Internal Medicine, - Metabolism and Gerontology, Vladimir SOSKA (Department of Clinical Biochemistry, St. Anne’s University Hospital Brno, 2nd Clinic of Internal Medicine, Masaryk University Brno, Volker JJ SCHETTLER (Centre of Nephrology G¨ottingen, Germany), Wolfgang REINHARDT (SUS Malmoe, Sweden), Xavier PINT´O (Hospital Universitari de Bellvitge-Idibell-UB-CiberObn, Spain), Yoto YOTOV (Second Cardiology Clinic, Marina, University Hospital Sv., Medical University of Varna, Zaneta PETRULIONIENE (Vilnius University Medical Faculty, Vilnius University Hospital Santaros klinikos, Lithuania), ˇZeljko REINER (Department for Metabolic Diseases, University Hospital Center Zagreb, and Croatia, ).
Subjects: Clinicians, Clinical evaluation, Cardiology and Cardiovascular Medicine, Cardiovascular risk, Lipoprotein(a)
Published: 2023

9. APOE Molecular Spectrum in a French Cohort with Primary Dyslipidemia

Author: Yara Abou Khalil, Oriane Marmontel, Jean Ferrières, François Paillard, Cécile Yelnik, Valérie Carreau, Sybil Charrière, Eric Bruckert, Antonio Gallo, Philippe Giral, Anne Philippi, Olivier Bluteau, Catherine Boileau, Marianne Abifadel, Mathilde Di-Filippo, Alain Carrié, Jean-Pierre Rabès, Mathilde Varret, Laboratoire de Recherche Vasculaire Translationnelle (LVTS (UMR_S_1148 / U1148)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord, Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), CHU Pontchaillou [Rennes], Centre de référence des maladies auto-immunes systémiques rares du Nord et Nord Ouest [CHRU Lille], Hôpital Claude Huriez [Lille], CHU Lille-CHU Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] (IHU ICAN), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Hospices Civils de Lyon (HCL), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] (IHU ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut Cochin (IC UM3 (UMR 8104 / U1016)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Sorbonne Université - Faculté de médecine [CHU Pitié Salpétrière], CIC Hôpital Bichat, AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-UFR de Médecine, Université de Versailles Saint-Quentin-en-Yvelines - UFR Sciences de la santé Simone Veil (UVSQ Santé), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Agence Nationale de la Recherche, ANR: ANR-16-RHUS-0007, Institut National de la Santé et de la Recherche Médicale, Inserm, Conseil National de la Recherche Scientifique, CNRS, This work was supported by grants from the national project CHOPIN (CHolesterol Person-alized Innovation) granted by the National Research Agency (ANR-16-RHUS-0007), INSERM (Institut National de la Santé et de la Recherche Médicale). YAK was supported by a grant from Ministère de l’Education Nationale et de la Technologie (France), a grant from Nouvelle Société Francophone de l’Athérosclérose (France), and grants from the Lebanese National Council for Scientific Research (CNRS-L) and the Council of Research of Saint-Joseph University of Beirut, Lebanon., and HAL UVSQ, Équipe
Subjects: hypercholesterolemia, ADH, FCHL, apolipoprotein E, APOE gene, mutation, variant, [SDV]Life Sciences [q-bio], Organic Chemistry, nutritional and metabolic diseases, General Medicine, Catalysis, Computer Science Applications, Inorganic Chemistry, [SDV] Life Sciences [q-bio], lipids (amino acids, peptides, and proteins), Physical and Theoretical Chemistry, Molecular Biology, Spectroscopy
Abstract: International audience; Primary hypercholesterolemia is characterized by elevated LDL-cholesterol (LDL-C) levels isolated in autosomal dominant hypercholesterolemia (ADH) or associated with elevated triglyceride levels in familial combined hyperlipidemia (FCHL). Rare APOE variants are known in ADH and FCHL. We explored the APOE molecular spectrum in a French ADH/FCHL cohort of 5743 unrelated probands. The sequencing of LDLR, PCSK9, APOB, and APOE revealed 76 carriers of a rare APOE variant, with no mutation in LDLR, PCSK9, or APOB. Among the 31 APOE variants identified here, 15 are described in ADH, 10 in FCHL, and 6 in both probands. Five were previously reported with dyslipidemia and 26 are novel, including 12 missense, 5 synonymous, 2 intronic, and 7 variants in regulatory regions. Sixteen variants were predicted as pathogenic or likely pathogenic, and their carriers had significantly lower polygenic risk scores (wPRS) than carriers of predicted benign variants. We observed no correlation between LDL-C levels and wPRS, suggesting a major effect of APOE variants. Carriers of p.Leu167del were associated with a severe phenotype. The analysis of 11 probands suggests that carriers of an APOE variant respond better to statins than carriers of a LDLR mutation. Altogether, we show that the APOE variants account for a significant contribution to ADH and FCHL.
Published: 2022
Full Text: View/download PDF

10. Validation and reproducibility of a short food frequency questionnaire for cardiovascular prevention

Author: François Paillard, Guillaume Mahé, Bruno Laviolle, Ophélie Flageul, C. Dourmap, Vincent Auffret, CHU Pontchaillou [Rennes], Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire Traitement du Signal et de l'Image (LTSI), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM), No funding, Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), and Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)
Subjects: medicine.medical_specialty, Cardiovascular risk factors, 030204 cardiovascular system & hematology, Alimentation, Validity, 03 medical and health sciences, 0302 clinical medicine, Cardiovascular prevention, Surveys and Questionnaires, Vegetables, Medicine, Dietary Questionnaire, Humans, 030212 general & internal medicine, Maladies cardiovasculaires, Validité, Reproducibility, Health professionals, business.industry, Questionnaire, Healthy subjects, Food frequency questionnaire, Reproducibility of Results, General Medicine, 3. Good health, Diet, Cardiovascular diseases, Fruit, Physical therapy, [SDV.IB]Life Sciences [q-bio]/Bioengineering, Cardiology and Cardiovascular Medicine, business, Reproductibilité
Abstract: International audience; BACKGROUND: Diet strongly influences cardiovascular risk. Dietary evaluation is a major issue in cardiovascular prevention, but few simple tools are available. Our team previously validated a short food frequency questionnaire; a new version of this questionnaire (Cardiovascular Dietary Questionnaire 2 [CDQ-2]) is easier to complete and more reliable. AIMS: To validate CDQ-2 in comparison with the original version, and to test its reproducibility. METHODS: CDQ-2 has 17 closed-ended questions; it provides a global dietary score that is a combination of specific scores for saturated, monounsaturated and omega-3 fatty acids, and fruit and vegetables. CDQ-2 was validated against the original version in two groups, who completed both questionnaires: 99 patients with cardiovascular risk factors and 50 healthy subjects. Reproducibility was assessed with 27 health professionals who completed the questionnaire twice, with a 1-month interval. RESULTS: The correlation coefficients of the scores between the two questionnaires ranged from 0.65 (monounsaturated fatty acids) to 0.93 (fruit and vegetables) (all P
Published: 2021
Full Text: View/download PDF

11. SAFEHEART risk-equation and cholesterol-year-score are powerful predictors of cardiovascular events in French patients with familial hypercholesterolemia

Author: Antonio Gallo, Sybil Charriere, Alexandre Vimont, M. John Chapman, Denis Angoulvant, Franck Boccara, Bertrand Cariou, Valérie Carreau, Alain Carrié, Eric Bruckert, Sophie Béliard, Sophie Beliard, Alain Carrie, Yves Cottin, Mathilde DI. Filippo, Sonia Dulong, Vincent Durlach, Michel Farnier, Emile Ferrari, Dorota Ferrieres, Jean Ferrieres, Philippe Giral, Sophie Gonbert, Regis Hankard, Jocelyn Inamo, Olga Kalmykova, Michel Krempf, Philippe Moulin, François Paillard, Noel Peretti, Agnes Perrin, Jean Pierre Rabes, Ariane Sultan, Patrick Tounian, René Valero, Bruno Verges, Cecile Yelnik, Olivier Ziegler, Inserm UMR1069, Nutrition, croissance et cancer (U 1069) (N2C), Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire catalyse et spectrochimie (LCS), Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-École Nationale Supérieure d'Ingénieurs de Caen (ENSICAEN), Normandie Université (NU)-Centre National de la Recherche Scientifique (CNRS), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Institute of cardiometabolism and nutrition (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service de Cardiologie (CHU Trousseau, Tours), CHU Trousseau [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Centre recherche en CardioVasculaire et Nutrition (C2VN), Institut National de la Santé et de la Recherche Médicale (INSERM)-Aix Marseille Université (AMU)-Institut National de la Recherche Agronomique (INRA), Centre de Recherche Saint-Antoine (CR Saint-Antoine), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Service d'endocrinologie-métabolisme [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), unité de recherche de l'institut du thorax UMR1087 UMR6291 (ITX), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), CHU Pitié-Salpêtrière [AP-HP], Station d'Amélioration Génétique des Animaux (SAGA), Institut National de la Recherche Agronomique (INRA), Centre Hospitalier Universitaire de Lyon, Service de Cardiologie [CHU de Dijon], Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Pôle Thoracique Cardiovasculaire et Neurologique, Hôpital Robert Debré, Point médical (Dijon), Hôpital Pasteur [Nice] (CHU), Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps (LEASP), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), Istituto di Scienze degli Alimenti e della Nutrizione, Università Cattolica del Sacro Cuore, Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Centre d' investigation clinique-plurithématique du CHU de Poitiers, Centre hospitalier universitaire de Poitiers (CHU Poitiers), Service de cardiologie, Hôpital Pierre Zobda-Quitman [CHU de la Martinique], CHU de la Martinique [Fort de France]-CHU de la Martinique [Fort de France], Samara State Technical University, Biologie et physiopathologie intestinales. Pharmacologie nutritionnelle, Université de Nantes (UN)-IFR26-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pontchaillou [Rennes], Hôpital Femme Mère Enfant, Laboratoire Interuniversitaire des Systèmes Atmosphériques (LISA (UMR_7583)), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Institut national des sciences de l'Univers (INSU - CNRS)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS), Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] (PhyMedExp), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Service de gastro-entérologie [CHU Trousseau], Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Trousseau [APHP], Nutrition, obésité et risque thrombotique (NORT), Aix Marseille Université (AMU)-Institut National de la Recherche Agronomique (INRA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d'Endocrinologie, Diabétologie et Maladies Métaboliques (CHU de Dijon), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Hôpital Jeanne d'Arc, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Tours, Institut national des sciences de l'Univers (INSU - CNRS)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Centre National de la Recherche Scientifique (CNRS), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] (IHU ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Pitié-Salpêtrière [AP-HP], Hospices Civils de Lyon (HCL), Public Health Expertise [Paris, France], Institut National de la Santé et de la Recherche Médicale (INSERM), Sorbonne Université (SU), Service d'Endocrinologie, Métabolisme et Prévention des Maladies Cardio-vasculaires [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Service de Cardiologie [CHU Saint-Antoine], CHU Saint-Antoine [AP-HP], Centre de Recherche Saint-Antoine (CRSA), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Unité de recherche de l'institut du thorax (ITX-lab), Service d'endocrinologie, diabète, maladies métaboliques [Hôpital de la Conception - APHM], Aix Marseille Université (AMU), Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (C2VN), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), French REgistry of Familial hypERCHOLesterolemia (REFERCHOL) investigators, ANR-16-RHUS-0007,CHOPIN,CHOPIN(2016), Gestionnaire, Hal Sorbonne Université, CHOPIN - - CHOPIN2016 - ANR-16-RHUS-0007 - RHUS - VALID, Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service d’Endocrinologie, Métabolisme et Prévention des Risques Cardio-Vasculaires [CHU Pitié-Salpêtrière], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Saint-Antoine [AP-HP], Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut National de la Recherche Agronomique (INRA)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS)
Subjects: cardiovascular risk, 0301 basic medicine, medicine.medical_specialty, cardiovascular risk equation, Population, Familial hypercholesterolemia, 030204 cardiovascular system & hematology, Risk Assessment, Cohort Studies, Hyperlipoproteinemia Type II, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Internal medicine, medicine, Humans, education, ComputingMilieux_MISCELLANEOUS, Risk equation, [SDV.MHEP.EM] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism, Entire population, education.field_of_study, familial hypercholesterolemia, business.industry, Cholesterol, External validation, Cholesterol, LDL, [SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism, medicine.disease, [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, 030104 developmental biology, cholesterol-year-score, chemistry, Cardiovascular Diseases, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, Clinical diagnosis, primary cardiovascular prevention, Cohort, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Cardiology and Cardiovascular Medicine, business, [SDV.AEN]Life Sciences [q-bio]/Food and Nutrition
Abstract: Background and aims Patients with heterozygous familial hypercholesterolemia (HeFH) present elevated cardiovascular (CV) risk. Current CV risk stratification algorithms developed for the general population are not adapted for heFH patients. It is therefore of singular importance to develop and validate CV prediction tools, which are dedicated to the HeFH population. Methods Our first objective was to validate the Spanish SAFEHEART-risk equation (RE) in the French HeFH cohort (REFERCHOL), and the second to compare SAFEHEART-RE with the low-density-lipoprotein-cholesterol (LDL-C)-year-score for the prediction of CV events in the HeFH French population. Results We included HeFH (n = 1473) patients with a genetic or clinical diagnosis (DLCN score ≥8). Among them, 512 patients with a 5-year follow-up were included to validate the 5 year-CV-RE. A total of 152 events (10.3%) occurred in the entire population of 1473 patients during a mean follow-up of 3.9 years. Over the five-year follow-up, non-fatal CV events occurred in 103 patients (20.2%). Almost all the parameters used in the SAFEHEART-RE were confirmed as strong predictors of CV events in the REFERCHOL cohort. The C-statistic revealed a satisfactory performance of both the SAFEHEART-RE and LDL-C-year-scores in predicting CV events for all the patients (primary and secondary prevention) (C-index 0.77 and 0.70, respectively) as well as for those in primary prevention at inclusion (C-index 0.78 and 0.77, respectively). Conclusions This analysis represents the first external validation of the SAFEHEART-RE and demonstrated that both SAFEHEART-RE and the LDL-C-year-score are good predictors of CV events in primary prevention HeFH patients.
Published: 2020
Full Text: View/download PDF

12. Progrès en prévention cardiovasculaire nutritionnelle

Author: François Paillard
Subjects: Nutrition and Dietetics
Published: 2018
Full Text: View/download PDF

13. Geographical variations in the prevalence of hypertension in France Cross-sectional analysis of the CONSTANCES cohort

Author: Lola Neufcourt, Sahar Bayat, François Paillard, Séverine Deguen, Marie Zins, Olivier Grimaud, Recherche en Pharmaco-épidémiologie et Recours aux Soins (REPERES), Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP), École des Hautes Études en Santé Publique [EHESP] (EHESP), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), CHU Pontchaillou [Rennes], Cohortes épidémiologiques en population (CONSTANCES), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay-Université Paris Cité (UPCité), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay-Université de Paris (UP)
Subjects: Adult, Male, medicine.medical_specialty, Adolescent, Social Determinants of Health, Cross-sectional study, Epidemiology, Blood Pressure, Disparities, 030204 cardiovascular system & hematology, Cardiovascular disease risk factors, Risk Assessment, Young Adult, 03 medical and health sciences, Sex Factors, 0302 clinical medicine, Risk Factors, Environmental health, Prevalence, medicine, Humans, 030212 general & internal medicine, Life Style, Aged, 2. Zero hunger, business.industry, Health Status Disparities, Middle Aged, Health Surveys, 3. Good health, Geographical variations, Cross-Sectional Studies, Socioeconomic Factors, Cohort, Hypertension, Female, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, France, Cardiology and Cardiovascular Medicine, business
Abstract: Aims While international variations in the prevalence of hypertension are well described, less is known about intra-national disparities and their determinants. We wanted to describe the variations in hypertension prevalence within France and to determine how much lifestyle and socioeconomic factors contributed to explain these regional variations. Methods Participants (62,247 French adults aged 18 to 69 years) were recruited in the 16 centres of the CONSTANCES study between 2012 and 2015. Hypertension was defined as blood pressure higher than 140/90 mmHg and/or taking antihypertensive medications. The contribution of lifestyle and socioeconomic factors to hypertension prevalence variations among centres was examined using sequential hierarchical logistic models. Results Hypertension prevalence was 37.3% (95% confidence interval (CI) = 36.6–38.0) in men and 23.2% (95% CI = 22.7–23.8) in women. Hypertension prevalence rates varied by almost two-fold among centres (1.9 in men, 1.6 in women) with the highest prevalence in the north and the east of France. Body mass index was strongly associated with hypertension in women (odds ratio (OR)1-unit increase = 1.11 (95% CI = 1.11–1.12)) and was the highest contributor to between-centre variations (27% in women), followed by socioeconomic characteristics (e.g. ORhigh versus low education = 0.85 (95% CI = 0.83–0.87), contributing to 14% of variations in women). Together, family history of hypertension, body mass index, education, occupation and residential area socioeconomic level explained about 30% and 40% of between-centre variations in men and women, respectively. Conclusion Hypertension prevalence greatly varies among French regions and this is partly explained by known lifestyle and socioeconomic factors. Nevertheless, these variations and all the hypertension determinants have not been fully deciphered yet.
Published: 2019
Full Text: View/download PDF

14. Six-year survival study after myocardial infarction: The EOLE prospective cohort study. Long-term survival after MI

Author: Caroline Dureau-Pournin, Jacques Benichou, Patrick Blin, Daniel Thomas, François Paillard, Cécile Droz-Perroteau, Serge Hercberg, Hélène Maizi, Louis Guize, Nicolas Danchin, Estelle Guiard, Jacques Tricoire, M.-A. Bernard, Nicholas Moore, Bordeaux population health (BPH), and Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)
Subjects: Male, medicine.medical_specialty, Adrenergic beta-Antagonists, Myocardial Infarction, Angiotensin-Converting Enzyme Inhibitors, 030226 pharmacology & pharmacy, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Secondary Prevention, medicine, Humans, Pharmacology (medical), Myocardial infarction, Prospective cohort study, Aged, PharmacoEpi-Drugs, Aspirin, Intention-to-treat analysis, Proportional hazards model, business.industry, Mortality rate, Hazard ratio, Middle Aged, medicine.disease, Survival Analysis, 3. Good health, Female, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, France, Hydroxymethylglutaryl-CoA Reductase Inhibitors, business, Platelet Aggregation Inhibitors, Follow-Up Studies, medicine.drug, Cohort study
Abstract: Summary Background Studies of survival after myocardial infarction (MI) are often based on intention to treat analyses of controlled trials. Objectives Describe long-term survival after MI in France. Methods Six-year cohort study of patients recruited within 3 months after MI. Primary outcome was all-cause death. Vital status was verified in the national death registry. Analysis used Cox models with time-dependent variables and propensity scores. Results Five thousand five hundred and twenty-seven (5527) subjects were included, 62.1±13 years old, 77.6% male, 9.6% smokers, 16.7% diabetic, 13.3% with previous MI. Up to 99% of patients were initially prescribed secondary prevention drugs (aspirin and/or other antiplatelet agents, beta-blockers, statins or other lipid-lowering agents, angiotensin converting enzyme inhibitors or angiotensin receptor blockers); 73% had all four classes. Overall 6-year mortality was 13.1% [95% confidence interval 12.3 to 14.0%], 2.34 per hundred patient-years (% PY); 49% returned all or all but one of the possible questionnaires (compliant [C]), 50.8% did not (non-compliant [NC]). The main predictors for death were non-compliance with study protocol (death rates NC 2.98% PY, C 1.69%PY, hazard ratio (HR) 3.13 [2.63–3.57]); increasing age at inclusion (HR up to 15.7 [10.7–23.2] for age ≥80); diabetes (1.39 [1.17–1.65]); smoking at inclusion (1.76 [1.27–2.44]), previous MI (1.46 [1.22–1.75]). Beta-blockers (0.79 [0.64–0.96]), statins (0.68 [0.51–0.90]), and enrolment in physical rehabilitation programs (0.74 [0.62–0.89]) were associated with a lower death rate. Conclusion Association of mortality with non-compliance to study protocol probably indicates general non-compliance with prevention. Analyses of treatment effects were hindered by paucity of events and of unexposed patients.
Published: 2019
Full Text: View/download PDF

15. Evaluation of short food-frequency questionnaires to assess the dietary pattern associated with atherosclerotic cardiovascular diseases

Author: Florian Congnard, Baptiste Quertier, François Paillard, Bénédicte Noury-Desvaux, Guillaume Mahé, Institut Formation Education Physique et Sportive Angers (IFEPSA), Université Catholique de l'Ouest (UCO), CHU Pontchaillou [Rennes], Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), and Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM)
Subjects: Male, [SDV]Life Sciences [q-bio], 030204 cardiovascular system & hematology, Diet Surveys, Food group, atherosclerosis 32, Young Adult, 03 medical and health sciences, 0302 clinical medicine, cardiovascular disease, Environmental health, Humans, Medicine, 030212 general & internal medicine, ComputingMilieux_MISCELLANEOUS, Food frequency, business.industry, questionnaire, food and beverages, Feeding Behavior, Dietary pattern, Atherosclerosis, Clinical Practice, Cross-Sectional Studies, Cardiovascular Diseases, Research Design, Female, Self Report, Cardiology and Cardiovascular Medicine, business, diet
Abstract: Cardiovascular diseases are strongly related to dietary habits. Diet can be assessed using dedicated questionnaires that can be self-completed by subjects but with the risk of errors.To compare the completion error rate of two questionnaires designed to assess dietary pattern linked to cardiovascular diseases and to study the correlation between the two questionnaires.Two questionnaires were used to assess dietary patterns of students: the 14-item Food-Frequency-Questionnaire (FFQ) that was validated against biomarkers, and the Cardiovascular-Dietary-Questionnaire 2 (CDQ2), which is a 19-item-FFQ derived from the previous 14-item FFQ. Both questionnaires assessed the intake of various food groups associated with either favourable or unfavourable effects on cardiovascular risk. A global dietary score was calculated for each questionnaire.FFQ and CDQ2 were completed by 150 sport degree students. In the case of FFQ, 111 questionnaires out of 150 (74.0%) were incomplete compared to only 1 CDQ2 out of 150 (0.7%) (P0.001). The correlation coefficient between the overall CDQ2 score and the FFQ dietary score was 0.53 (P0.01).The self-completion of CDQ2 compared to FFQ was associated with far less errors. There was a significant correlation between CDQ2 and FFQ. Preference should be given to CDQ2 in clinical practice and in studies where dietary pattern are evaluated without any interviewer.
Published: 2018
Full Text: View/download PDF

16. A minimal resting time of 25 min is needed before measuring stabilized blood pressure in subjects addressed for vascular investigations

Author: Guillaume, Mahe, Emmanuelle, Comets, Aziz, Nouni, François, Paillard, Caroline, Dourmap, Alexis, Le Faucheur, Vincent, Jaquinandi, Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pontchaillou [Rennes], Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC), Service de cardiologie et maladies vasculaires [Rennes] = Cardiac, Thoracic, and Vascular Surgery [Rennes], École normale supérieure - Rennes (ENS Rennes), Laboratoire Mouvement Sport Santé (M2S), École normale supérieure - Cachan (ENS Cachan)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Université de Brest (UBO)-Université de Rennes 2 (UR2), Université de Rennes (UNIV-RENNES)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Jonchère, Laurent, Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Université de Rennes (UR)-École normale supérieure - Rennes (ENS Rennes)-Université de Brest (UBO)-Université de Rennes 2 (UR2)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )
Subjects: Male, Time Factors, Systole, [SDV.MHEP.PHY] Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO], Rest, lcsh:R, lcsh:Medicine, Blood Pressure, Blood Pressure Determination, Models, Biological, Article, [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Diastole, Heart Rate, Hypertension, [SDV.MHEP.PHY]Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO], Humans, Female, lcsh:Q, Vascular Diseases, lcsh:Science, ComputingMilieux_MISCELLANEOUS, Aged
Abstract: Blood pressure (BP) measurement is a central element in clinical practice. According to international recommendations 3 to 5 minutes of resting is needed before blood pressure measurement. Surprisingly, no study has modelled the time course of BP decrease and the minimum resting-time before BP measurement. A cross-sectional bicentric observational study was performed including outpatients addressed for vascular examination. Using two automatic BP monitors we recorded the blood pressure every minute during 11 consecutive minutes. The data was analyzed by non-linear mixed effect regression. Systolic (SBP) and diastolic BPs were studied and we tested the effect of covariates on its evolution through log-likelihood ratio tests. We included 199 patients (66+/−13years old). SBP was found to decrease exponentially. Simulations based on the final model show that only half the population reaches a stabilized SBP (defined as SBP + 5 mmHg) after 5 min of resting-time while it takes 25 min to ensure 90% of the population has a stabilized SBP. In conclusion, our results and simulations suggest that 5 minutes are not enough to achieve a stabilized SBP in most patients and at least 25 minutes are required. This questions whether the diagnosis of hypertension can be reliably made during routine visits in general practitioners’ offices.
Published: 2017
Full Text: View/download PDF

17. Effets du chocolat sur la physiologie et les pathologies cardiovasculaires

Author: François Paillard
Subjects: chemistry.chemical_classification, medicine.medical_specialty, business.industry, food and beverages, Vasodilation, Stimulation, General Medicine, medicine.disease, No donors, Endocrinology, Flavonols, Insulin resistance, Blood pressure, chemistry, Decreased Platelet Aggregation, Internal medicine, Decreased lipid, Medicine, business
Abstract: Cocoa has a high content in polyphenols, especially flavonols. Flavonols exert a favourable effect on endothelium-derived vasodilation via the stimulation of nitric oxide-synthase (NOS), the increased availability of l-arginine (NO donor) and the decreased degradation of NO. Cocoa may also have a beneficial effect via the decreased platelet aggregation, the decreased lipid oxidation and insulin resistance. These effects are associated with a modest decrease of blood pressure and a favourable trend towards a reduction in cardiovascular events and strokes.
Published: 2014
Full Text: View/download PDF

18. A consensus statement on lipid management after acute coronary syndrome

Author: François Schiele, Michel Farnier, Michel Krempf, Eric Bruckert, Jean Ferrières, Denis Angoulvant, Franck Boccara, Jacques Bonnet, Jean-Louis Bonnet, Guillaume Cayla, Marion Chatot, Romain Chopard, Jean-Philippe Collet, Nicolas Danchin, Gregory Ducrocq, Meyer Elbaz, Emile Ferrari, Michel Galinier, Edouard Gerbaud, Dominique Guedj, Serge Kownator, Gilles Lemesle, Laszlo Levai, Nicolas Mansencal, Jacques Mansourati, Christophe Meune, Olivier Morel, François Paillard, Christophe Piot, Vincent Probst, Etienne Puymirat, François Roubille, Pierre Sabouret, Emmanuel Teiger, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Point médical (Dijon), Centre hospitalier universitaire de Nantes (CHU Nantes), Service d’Endocrinologie, Métabolisme et Prévention des Risques Cardio-Vasculaires [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut E3M [CHU Pitié-Salpêtrière], Service de cardiologie [Toulouse], Hôpital de Rangueil, CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse], Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), and Université de Montpellier (UM)
Subjects: medicine.medical_specialty, Acute coronary syndrome, Consensus, Statement (logic), Decision Making, Familial hypercholesterolemia, 030204 cardiovascular system & hematology, Critical Care and Intensive Care Medicine, statins, 03 medical and health sciences, 0302 clinical medicine, Ezetimibe, medicine, Humans, In patient, 030212 general & internal medicine, Medical prescription, Acute Coronary Syndrome, Intensive care medicine, Hypolipidemic Agents, Lipid management, lipid-lowering therapy, business.industry, Disease Management, General Medicine, medicine.disease, Lipids, 3. Good health, LDL cholesterol, Physical therapy, familial hypercholesterolaemia, LDL Cholesterol Lipoproteins, lipids (amino acids, peptides, and proteins), Cardiology and Cardiovascular Medicine, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Algorithms, medicine.drug, ezetimibe
Abstract: International audience; In patients admitted for acute coronary syndrome (ACS), the guidelines of the European Society of Cardiology give a Class I, Level A recommendation for the prescription of high-intensity statins to be initiated as early as possible, regardless of the low-density lipoprotein cholesterol (LDL-C) level. Although statins are widely prescribed after ACS, the intensity of therapy and the proportion of patients achieving target LDL-C values are often not in line with recommendations due to a lack of compliance with guidelines by the physicians, a lack of compliance with treatment or poor tolerance by patients, and poor dose adaptation. In this context, a group of French physicians came together to define strategies to facilitate and improve the management of lipid-lowering therapy after ACS. This paper outlines the scientific rationale for the use of statins at the acute phase of ACS, the utility of ezetimibe, the measurement of LDL-C during the course of ACS, the opportunities for detecting familial hypercholesterolaemia and the results of the consensus for the management of lipid-lowering therapy, illustrated in two decision-making algorithms.
Published: 2016
Full Text: View/download PDF

19. Effects of Sauna Alone and Postexercise Sauna Baths on Blood Pressure and Hemodynamic Variables in Patients With Untreated Hypertension

Author: Manon Bélanger, François Paillard, Anil Nigam, Mathieu Gayda, Mauricio Garzon, Martin Juneau, Philippe Sosner, and Mariel Gonzalez
Subjects: medicine.medical_specialty, Ambulatory blood pressure, business.industry, Endocrinology, Diabetes and Metabolism, Hemodynamics, Stroke volume, Blood pressure, Mean blood pressure, medicine.anatomical_structure, Internal medicine, Heart rate, Internal Medicine, medicine, Cardiology, Physical therapy, Vascular resistance, Exercise physiology, Cardiology and Cardiovascular Medicine, business
Abstract: The effects of sauna alone vs exercise and sauna on ambulatory blood pressure monitoring and central hemodynamic variables were measured in 16 patients with untreated hypertension assigned to a control period, sauna, or exercise and sauna. Exercise and sauna had positive effects on 24-hour systolic and mean blood pressure in patients with untreated hypertension. Exercise and sauna and sauna alone reduce total vascular resistance, with positive effects lasting up to 120 minutes after heat exposure.
Published: 2012
Full Text: View/download PDF

20. French Society of Cardiology guidelines for cardiac rehabilitation in adults

Author: Richard Brion, François Paillard, Anne Borgne, Frédérique Claudot, Dany Marcadet, Claire Mounier-Vehier, Michel Fischbach, Silla Consoli, Alain Cohen-Solal, François Carré, Marie-Christine Iliou, Bernard Pierre, Bénédicte Vergès-Patois, Daniel Thomas, Patrick Aeberhard, Jean-Michel Lecerf, Bruno Pavy, Claudie Argouach, Catherine Monpère, Laurent Fourcade, Bernard Swynghedauw, Sonia Corone, Yves Theodose, and Hervé Douard
Subjects: Adult, Male, Health Knowledge, Attitudes, Practice, medicine.medical_specialty, Activities of daily living, Heart Diseases, Entraînement physique, Cost-Benefit Analysis, medicine.medical_treatment, Cardiology, MEDLINE, Cardiac rehabilitation, Health knowledge, 030204 cardiovascular system & hematology, Therapeutic education, Exercise training, 03 medical and health sciences, 0302 clinical medicine, Patient Education as Topic, Internal medicine, Activities of Daily Living, medicine, Humans, 030212 general & internal medicine, Réadaptation cardiaque, Aged, Patient Care Team, Evidence-Based Medicine, Rehabilitation, Delivery of Health Care, Integrated, business.industry, Patient Selection, Société française de cardiologie, Health Care Costs, General Medicine, Middle Aged, Mental health, Exercise Therapy, Mental Health, Female, France, French guidelines, Recommandations françaises, Cardiology and Cardiovascular Medicine, business, Risk Reduction Behavior, Éducation thérapeutique
Abstract: text isan extract from thereference ‘‘Good Practice for Cardiac Rehabilitation inAdults 2011’’, which available onwebsite of GERS (Groupe Exercice Readaptation Sport of the French Society of Cardiology [Societe franc¸aise de cardiologie];http://www.sfcardio.fr/groupes/groupes/exercice-readaptation-sport) and contains the complete bibliography, replacing the FrenchSociety of Cardiology text of 2002, version 2, establishing recommendations for cardiac rehabilitation in adults.
Published: 2012
Full Text: View/download PDF

21. The Antidote to the Global Lies in the Singular: an Interview with Jean Baudrillard

Author: Jean-François Paillard
Subjects: Cultural Studies, Psychoanalysis, Sociology and Political Science, Communication, medicine.medical_treatment, medicine, Sociology, Criminology, Antidote
Published: 2011
Full Text: View/download PDF

22. LONG-TERM SURVIVAL AFTER MYOCARDIAL INFARCTION IN A SIX-YEAR FOLLOW-UP COHORT, EOLE

Author: Jacques Benichou, François Paillard, Jacques Tricoire, Caroline Dureau-Pournin, Nicholas Moore, M.-A. Bernard, Daniel Thomas, Patrick Blin, Serge Hercberg, Nicolas Danchin, and Cécile Droz-Perroteau
Subjects: medicine.medical_specialty, business.industry, Internal medicine, Long term survival, Cohort, Cardiology, Medicine, Myocardial infarction, Cardiology and Cardiovascular Medicine, business, medicine.disease
Published: 2018
Full Text: View/download PDF

23. Sustained positive impact of a coronary rehabilitation programme on adherence to dietary recommendations

Author: Karine Ligier, François Paillard, Bruno Laviolle, Jean-Claude Daubert, Catherine Letellier, Pascal Guillo, Christèle Froger-Bompas, Service de cardiologie et maladies vasculaires [Rennes] = Cardiac, Thoracic, and Vascular Surgery [Rennes], CHU Pontchaillou [Rennes], Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), and Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM)
Subjects: Counseling, Male, Health Knowledge, Attitudes, Practice, Time Factors, medicine.medical_treatment, MESH: Health Knowledge, Attitudes, Practice, MESH: Food Habits, Réadaptation, Ascorbic Acid, Coronary Artery Disease, 030204 cardiovascular system & hematology, MESH: Erythrocyte Membrane, Gastroenterology, 0302 clinical medicine, MESH: Practice Guidelines as Topic, [INFO.INFO-TS]Computer Science [cs]/Signal and Image Processing, Surveys and Questionnaires, MESH: Ascorbic Acid, MESH: Coronary Artery Disease, 030212 general & internal medicine, MESH: Treatment Outcome, 2. Zero hunger, chemistry.chemical_classification, MESH: Program Evaluation, MESH: Middle Aged, Biological markers, Rehabilitation, MESH: Counseling, MESH: Fatty Acids, Unsaturated, General Medicine, Middle Aged, MESH: Nutrition Assessment, MESH: Nutritional Status, MESH: Patient Compliance, Dietary advice, Lipids, 3. Good health, Coronary heart disease, Erythrocyte membrane, Treatment Outcome, MESH: Risk Reduction Behavior, Practice Guidelines as Topic, Fatty Acids, Unsaturated, [SDV.IB]Life Sciences [q-bio]/Bioengineering, Marqueurs biologiques, Cardiology and Cardiovascular Medicine, [SPI.SIGNAL]Engineering Sciences [physics]/Signal and Image processing, Polyunsaturated fatty acid, Adult, medicine.medical_specialty, Prévention, Group ii, Nutritional Status, MESH: Patient Education as Topic, MESH: Folic Acid, 03 medical and health sciences, Folic Acid, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Patient Education as Topic, Internal medicine, medicine, Humans, In patient, Nutrition, MESH: Humans, Vitamin C, Questionnaire, business.industry, MESH: Questionnaires, Prevention, MESH: Time Factors, Erythrocyte Membrane, MESH: Biological Markers, MESH: Adult, Feeding Behavior, MESH: Lipids, MESH: Male, Diet, Surgery, Maladie coronaire, Nutrition Assessment, chemistry, Patient Compliance, business, Risk Reduction Behavior, Biomarkers, Program Evaluation
Abstract: International audience; BACKGROUND: Nutrition has a major influence after coronary events but long-term adherence to dietary advice is poorly evaluated. AIM: To evaluate if a cardiovascular rehabilitation programme including dietary counselling has a positive impact on adherence to dietary recommendations. METHODS: Two groups of coronary patients were compared in an observational non-randomized study. Group I included 32 patients at the acute phase of a coronary syndrome and group II included 104 patients between six months and three years after completing a cardiovascular rehabilitation programme. The evaluation was performed with (1) a validated 14-item food frequency questionnaire (FFQ), which gives scores for the consumption of saturated fatty acids (SFA), monounsaturated fatty acids (MUFA), Omega-6 and Omega-3 polyunsaturated fatty acids (PUFA), fruits and vegetables, and a global cardiovascular protective dietary score; and (2) biological markers. RESULTS: SFA score was higher in group I vs II (7.4+/-2.8 vs 4.4+/-2.1, p
Published: 2009
Full Text: View/download PDF

24. Phytosterols: Focus on ANSES guidelines

Author: J.M. Bard, François Paillard, Frédéric Fumeron, Jean-Michel Lecerf, Bruno Vergès, Centre de Recherche des Cordeliers (CRC), Université Pierre et Marie Curie - Paris 6 (UPMC)-École Pratique des Hautes Études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), FR 3473 Institut universitaire Mer et Littoral (IUML), Le Mans Université (UM)-Université d'Angers (UA)-Université de Nantes (UN)-École Centrale de Nantes (ECN)-Université de Bretagne Sud (UBS)-Institut Français de Recherche pour l'Exploitation de la Mer (IFREMER)-Centre National de la Recherche Scientifique (CNRS), Institut de Cancérologie de l'Ouest [Angers/Nantes] (UNICANCER/ICO), UNICANCER, Centre de recherche en nutrition humaine Ouest, Service d'Endocrinologie, Diabétologie et Maladies Métaboliques (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Lipides - Nutrition - Cancer (U866) (LNC), Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon (ENSBANA), Service de cardiologie et maladies vasculaires [Rennes] = Cardiac, Thoracic, and Vascular Surgery [Rennes], CHU Pontchaillou [Rennes], Service de nutrition, Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP), Université Pierre et Marie Curie - Paris 6 (UPMC)-École pratique des hautes études (EPHE), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Bourgogne (UB)-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon (ENSBANA)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement, Service de cardiologie et maladies vasculaires, Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-CHU Pontchaillou [Rennes], Administateur, HAL Sorbonne Université, Centre de Recherche des Cordeliers ( CRC ), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -École pratique des hautes études ( EPHE ) -Université Paris Diderot - Paris 7 ( UPD7 ) -Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), FR 3473 Institut universitaire Mer et Littoral ( IUML ), Université de Bretagne Sud ( UBS ) -Le Mans Université ( UM ) -Université d'Angers ( UA ) -Centre National de la Recherche Scientifique ( CNRS ) -Institut Français de Recherche pour l'Exploitation de la Mer ( IFREMER ) -Université de Nantes ( UN ) -École Centrale de Nantes ( ECN ), Institut de Cancérologie de l'Ouest, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand ( CHU Dijon ), Lipides - Nutrition - Cancer (U866) ( LNC ), Université de Bourgogne ( UB ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon ( ENSBANA ), Université de Rennes 1 ( UR1 ), Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -Hôpital Pontchaillou-CHU Pontchaillou [Rennes], and Réseau International des Instituts Pasteur ( RIIP ) -Réseau International des Instituts Pasteur ( RIIP )
Subjects: Risque cardiovasculaire, Nutrition and Dietetics, [ SDV.AEN ] Life Sciences [q-bio]/Food and Nutrition, Medicine (miscellaneous), lcsh:TP670-699, Individual response, [ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Cardiovascular risk, Biochemistry, Réponse individuelle, Plant sterols, [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, 3. Good health, [SDV.AEN] Life Sciences [q-bio]/Food and Nutrition, Cholesterol, Absorption intestinale et synthèse, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Intestinal absorption and synthesis, cholestérol, absorption intestinale et synthèse, Phytostérols, LDL-cholestérol, lcsh:Oils, fats, and waxes, Agronomy and Crop Science, [SDV.AEN]Life Sciences [q-bio]/Food and Nutrition, Food Science
Abstract: Recently, ANSES gave a prudent advice concerning consumption of plant sterols/stanols in order to lower cardiovascular risk. In particular, two of the main reasons for this advice were the inter-individual variability in the response to diet supplemented with these products on one side, and a relationship between plasma levels of plant sterols and cardiovascular risk on the other side. These two points are discussed in the present review. There is a large inter-individual variability in the response to plant sterols/stanols consumption, with a lack of response (LDLC lowering) in 20–42% of the subjects. In some of the non-responders, plasma LDLC were found to be increased. LDLC decrease is correlated with initial LDLC concentration. The response is positively correlated with cholesterol absorption and inversely with synthesis rate. The genetic influence on response remains to demonstrate since most of the studies on this matter were statistically underpowered. Concerning relationship between phytosterolemia and cardiovascular risk, many discrepant results have been published. A recent meta-analysis has shown a lack of association, but there was significant heterogeneity between studies, which precludes from firm conclusions. In genome wide association studies, variants associated with higher plasma plant sterol levels were also associated with higher cardiovascular risk. Phytosterolemia is correlated with cholesterol absorption. Absorption might be the causative factor of the relationship between plasma plant sterols and cardiovascular risk, but a direct deleterious effect of the phytostérols cannot be excluded. The ANSES considered that clinical studies are needed before conclusions on the cardiovascular impact of plant sterols/stanols consumption can be drawn., Récemment, l’ANSES a rendu un avis prudent sur la consommation des phytostérols/stanols dans le but de réduire le risque cardiovasculaire. Parmi les principales raisons justifiant la prudence de l’ANSES figurent notamment, d’une part, la variabilité inter-individuelle de la réponse à la consommation de phytostérols/stanols, et, d’autre part, les relations entre phytostérolémie plasmatique et risque cardiovasculaire. Ces deux points font l’objet de la présente revue. Il existe une variabilité de la réponse individuelle à l’apport de stérols/stanols végétaux, avec une absence de réponse (baisse LDLC) chez 20 à 42 % des sujets. Parmi les sujets non répondeurs, certains augmentent le LDLC. La diminution du cholestérol LDLC est proportionnelle à sa concentration initiale en valeur absolue et constante en pourcentage. La réponse est corrélée négativement au taux de synthèse du cholestérol et positivement au niveau d’absorption. L’effet des facteurs génétiques sur la réponse reste encore à démontrer. Il existe un manque général de puissance statistique dans toutes les études génétiques publiées à ce jour. Concernant la relation entre phytostérolémie et le risque cardiovasculaire, de nombreux résultats contradictoires ont été publiés. Une méta-analyse montre globalement une absence de relation, mais l’hétérogénéité significative entre ces études ne permet pas de conclure. D’autre part, des études génétiques montrent que les variants qui augmentent la phytostérolémie sont associés à une augmentation du risque. La phytostérolémie est liée à l’absorption du cholestérol. L’absorption pourrait être le facteur causal de la relation entre phytostérolémie et risque cardiovasculaire, mais il n’est pas exclu que les phytostérols circulants aient aussi un effet délétère. L’ANSES estime que des études cliniques sont nécessaires pour conclure sur l’impact cardiovasculaire de la consommation des produits contenant des phytostérols/stanols.
Published: 2015
Full Text: View/download PDF

25. Les mesures nutritionnelles dans l’hypertension artérielle

Author: François Paillard
Subjects: Gynecology, medicine.medical_specialty, business.industry, Medicine, General Medicine, business
Abstract: Points essentiels Les facteurs nutritionnels peuvent expliquer 30 a 75 % des cas d’hypertension arterielle (HTA) selon les populations. L’exces ponderal peut a lui seul expliquer 11 a 25 % des cas. Les mesures nutritionnelles sont efficaces pour reduire le niveau tensionnel ou retarder l’apparition de l’HTA. Globalement elles ont un impact voisin de celui d’une monotherapie antihypertensive et en potentialisent l’efficacite. L’efficacite du regime Dash est particulierement demontree. Il est pauvre en graisses saturees et en sodium, riche en fruits, legumes et produits laitiers ecremes.
Published: 2006
Full Text: View/download PDF

26. [Effects of chocolate consumption on physiology and cardiovascular diseases]

Author: François, Paillard
Subjects: Cardiovascular Physiological Phenomena, Cacao, Cardiovascular Diseases, Humans
Abstract: Cocoa has a high content in polyphenols, especially flavonols. Flavonols exert a favourable effect on endothelium-derived vasodilation via the stimulation of nitric oxide-synthase (NOS), the increased availability of l-arginine (NO donor) and the decreased degradation of NO. Cocoa may also have a beneficial effect via the decreased platelet aggregation, the decreased lipid oxidation and insulin resistance. These effects are associated with a modest decrease of blood pressure and a favourable trend towards a reduction in cardiovascular events and strokes.
Published: 2014

27. A multicenter, open-label, randomized study comparing the efficacy of atorvastatin versus usual care in reducing refractory hypercholesterolemia in high-risk patients to target levels

Author: Jean-Jacques Portal, Thierry Roux, François Paillard, Gilbert Habib, Pascal Maigret, Jean-François Angellier, and Guillaume Charpentier
Subjects: Pharmacology, medicine.medical_specialty, Fenofibrate, business.industry, Atorvastatin, Cerivastatin, Gastroenterology, Surgery, law.invention, Randomized controlled trial, law, Simvastatin, Internal medicine, medicine, Gemfibrozil, lipids (amino acids, peptides, and proteins), Pharmacology (medical), business, Pravastatin, medicine.drug, Fluvastatin
Abstract: Objective: This multicenter, open-label, randomized, parallel-arm study was undertaken to compare the efficacy and safety of atorvastatin 10, 20, and 40 mg/d with usual care in high-risk hypercholesterolemic patients refractory to their current lipid-lowering therapy (monotherapy under fibrates, statins [atorvastatin excluded], or resins). Methods: Seven hundred seventy patients (516 men, 254 women) aged 58.8 ± 10.1 years with persistent hypercholesterolemia (low-density lipoprotein cholesterol [LDL-C] level at inclusion, 175 ± 39 mg/dL) were assigned randomly after a 4-week run-in period during which they continued their existing lipid-lowering therapy. Most (57.5%) of the patients had a personal history of coronary heart disease. Results: After 12 weeks of treatment, 36.6% of patients achieved recommended LDL-C target levels in the atorvastatin group (group A) compared with 11.2% in the usual-care group (group B) ( P = 0.001). Usual care included adjusting doses, switching drugs, combining drugs,and prescribing aggressive dietary treatments. The drugs used in group B were bezafibrate, ciprofibrate, fenofibrate, gemfibrozil, fluvastatin, pravastatin, simvastatin, and cerivastatin. The mean level of LDL-C decreased from 177 mg/dL to 129 mg/dL (25.82%) in group A and from 174 mg/dL to 154 mg/dL (10.35%) in group B ( P = 0.001). After 4 weeks of treatment, LDL-C target values were achieved by 22.9% of patients in group A at the lowest dose (10. mg/d) and by 5.2% in group B ( P
Published: 2000
Full Text: View/download PDF

28. High-density lipoprotein cholesterol and triglycerides in the statin era: A pending issue?

Author: François Paillard
Subjects: medicine.medical_specialty, Statin, medicine.drug_class, Syndrome métabolique, Gastroenterology, Statines, chemistry.chemical_compound, High-density lipoprotein, Internal medicine, medicine, Triglycérides, Triglycerides, Cholesterol, business.industry, Hypertriglyceridemia, Statins, HDL-Cholestérol, nutritional and metabolic diseases, General Medicine, medicine.disease, Metabolic syndrome, chemistry, Simvastatin, HDL-Cholesterol, lipids (amino acids, peptides, and proteins), Cardiology and Cardiovascular Medicine, business, Heart Protection Study, medicine.drug, Lipoprotein
Abstract: MOTS CLES HDL-Cholesterol ; Triglycerides ; Statines ; Syndrome metabolique Statins are highly effective for lowering low-density lipoprotein (LDL) cholesterol and reaching LDL targets, but have a limited impact on triglycerides and high-density lipoprotein (HDL) cholesterol. In this issue of the journal, Laforest et al. demonstrate that high triglyceride and low HDL-cholesterol concentrations are frequent in patients treated with hypolipidaemic agents, mostly statins [1]. In this study, patients with high triglycerides and low HDL-cholesterol also had more additional risk factors, in particular diabetes and hypertension. These findings raise questions about the relevance of lipid disturbances with statin treatment in high-risk patients. Is there any point in paying attention to hypertriglyceridemia and low HDL-cholesterol in these patients? Studies in families with premature coronary disease have indeed shown that a low HDL level was the most common abnormality and was most often associated with Hypertriglyceridemia [2]. In recent statin trials in high-risk patients, the prevalence of an HDL-cholesterol concentration less than 43mg/dl was high, between 40% [3] and 60% [4]. Low HDL-cholesterol was predictive of major cardiovascular events. In the placebo arm of the Heart protection study (HPS), patients with HDL-cholesterol less than 35mg/dl had a 43% higher risk than those with HDL-cholesterol greater than 43mg/dl [4]. Treatment with simvastatin decreased this gap only moderately (33% higher risk for HDL-cholesterol less than 35mg/dl while on statin treatment). An excess of risk remained in patients with low HDL-cholesterol receiving a high dosage of statin and in
Published: 2009
Full Text: View/download PDF

29. Effects of sauna alone and postexercise sauna baths on blood pressure and hemodynamic variables in patients with untreated hypertension

Author: Mathieu, Gayda, François, Paillard, Philippe, Sosner, Martin, Juneau, Mauricio, Garzon, Mariel, Gonzalez, Manon, Bélanger, and Anil, Nigam
Subjects: Adult, Male, Cross-Over Studies, Time Factors, Hemodynamics, Blood Pressure, Stroke Volume, Blood Pressure Monitoring, Ambulatory, Middle Aged, Original Papers, Steam Bath, Treatment Outcome, Heart Rate, Hypertension, Humans, Female, Vascular Resistance, Cardiac Output, Exercise, Aged
Abstract: J Clin Hypertens (Greenwich). 2012;00:00–00 ©2012 Wiley Periodicals, Inc. The effects of sauna alone vs exercise and sauna on ambulatory blood pressure monitoring and central hemodynamic variables were measured in 16 patients with untreated hypertension assigned to a control period, sauna, or exercise and sauna. Exercise and sauna had positive effects on 24‐hour systolic and mean blood pressure in patients with untreated hypertension. Exercise and sauna and sauna alone reduce total vascular resistance, with positive effects lasting up to 120 minutes after heat exposure.
Published: 2012

30. Heterogeneity of dietary profiles in highly sedentary young Guadeloupean women

Author: François Paillard, Sophie Antoine-Jonville, Bruno Laviolle, Olivier Hue, Stéphane Sinnapah, Adaptations au Climat Tropical, Exercice et Santé (ACTES), Université des Antilles et de la Guyane (UAG), Pharmacologie du Sepsis et Choc Septique, Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de cardiologie et maladies vasculaires [Rennes] = Cardiac, Thoracic, and Vascular Surgery [Rennes], CHU Pontchaillou [Rennes], and Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM)
Subjects: Gerontology, Health Behavior, Medicine (miscellaneous), MESH: Food Habits, 030204 cardiovascular system & hematology, Body Mass Index, Correlation, 0302 clinical medicine, Surveys and Questionnaires, Medicine, Cluster Analysis, MESH: Obesity, Orthopedics and Sports Medicine, Nutritional Physiological Phenomena, 030212 general & internal medicine, Guadeloupe, West indies, 2. Zero hunger, Principal Component Analysis, Nutrition and Dietetics, MESH: Diet Surveys, Food frequency questionnaire, General Medicine, Adaptation, Physiological, Quartile, MESH: Young Adult, Female, MESH: Sedentary Lifestyle, MESH: Health Behavior, Physical activity, Diet Surveys, MESH: Body Mass Index, 03 medical and health sciences, Young Adult, MESH: Diet, Humans, MESH: Guadeloupe, Obesity, MESH: Nutritional Physiological Phenomena, Exercise, MESH: Principal Component Analysis, MESH: Humans, Recall, business.industry, MESH: Questionnaires, Feeding Behavior, MESH: Adaptation, Physiological, MESH: Cluster Analysis, Physical activity level, Diet, MESH: Exercise, Fruit intake, Sedentary Behavior, business, MESH: Female, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Demography
Abstract: Objective:The aim was to examine the relationship between physical activity pattern and dietary profile. Although some clustering of the variables related to these major determinants of cardiovascular risk has been demonstrated, they have not been extensively studied together.Participants, Design, and Setting:Two hundred two female university students from the main Guadeloupe (French West Indies) campus participated. They self-administered a validated Food Frequency Questionnaire and the 1-yr recall Modifiable Activity Questionnaire. Principal-component analysis was performed on the scores and the variables related to the physical activity pattern and dietary profile.Results:A model including 10 variables explained 84.9% of the total variance. The physical activity pattern was not associated with the dietary profile, apart from fruit intake. The physical activity level was homogeneously low (median 1.58, first and last quartile cutoffs 1.54 and 1.66, respectively). There was no correlation between the physical activity level and the Food Frequency Questionnaire score (r = –.005).Conclusions:The absence of a strong relationship between the food and physical activity profiles is interpreted as a possible reflection of a dysregulation of the quality of food intake in this population with a sedentary lifestyle.
Published: 2010
Full Text: View/download PDF

31. An unfavorable dietary pattern is associated with symptomatic ischemic stroke and carotid atherosclerosis

Author: François Paillard, Véronique Golfier, Guillaume Mahé, Jean-Michel De Bray, Bruno Laviolle, Thomas Ronzière, Thomas Cochery, Biologie Neurovasculaire et Mitochondriale Intégrée (BNMI), Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service de Neurologie [Rennes] = Neurology [Rennes], CHU Pontchaillou [Rennes], Pharmacologie du Sepsis et Choc Septique, Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM)-Service de Pharmacologie [Rennes], CHU Pontchaillou [Rennes]-CHU Pontchaillou [Rennes], Service de neurologie [Angers], Université d'Angers (UA)-Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM), Service de cardiologie et maladies vasculaires [Rennes] = Cardiac, Thoracic, and Vascular Surgery [Rennes], and Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM)-Service de Pharmacologie [Rennes]
Subjects: Carotid Artery Diseases, Male, MESH: Food Habits, 030204 cardiovascular system & hematology, Gastroenterology, Brain Ischemia, Brain ischemia, Fatty Acids, Monounsaturated, Hospitals, University, 0302 clinical medicine, MESH: Fatty Acids, Omega-3, Risk Factors, MESH: Risk Factors, Vegetables, MESH: Diet Records, MESH: Fatty Acids, Omega-6, Stroke, chemistry.chemical_classification, Ultrasonography, Doppler, Duplex, MESH: Middle Aged, Cerebral infarction, Fatty Acids, food and beverages, MESH: Brain Ischemia, MESH: Life Style, Middle Aged, MESH: Case-Control Studies, Diet Records, 3. Good health, MESH: Fatty Acids, MESH: Fatty Acids, Monounsaturated, Female, France, Cardiology and Cardiovascular Medicine, MESH: Fruit, Polyunsaturated fatty acid, Adult, medicine.medical_specialty, MESH: Ultrasonography, Doppler, Duplex, [SDV.MHEP.CHI]Life Sciences [q-bio]/Human health and pathology/Surgery, Hospitals, General, MESH: Stroke, Central nervous system disease, Duplex scanning, 03 medical and health sciences, MESH: Diet, Internal medicine, Fatty Acids, Omega-6, Fatty Acids, Omega-3, medicine, Humans, Life Style, MESH: Hospitals, University, MESH: Humans, Vascular disease, business.industry, MESH: Carotid Artery Diseases, Case-control study, MESH: Hospitals, General, MESH: Adult, Feeding Behavior, medicine.disease, MESH: Vegetables, MESH: Male, Surgery, Diet, MESH: France, chemistry, Case-Control Studies, Fruit, business, MESH: Female, 030217 neurology & neurosurgery
Abstract: International audience; OBJECTIVE: Ischemic strokes represent more than 80% of total strokes in Western countries. The influence of dietary factors on ischemic stroke risk is debated mainly because available data are limited. Our objective was to compare the dietary pattern of symptomatic ischemic stroke patients under 65 years old with control subjects using a validated 14-item food frequency questionnaire (FFQ). We also compared symptomatic ischemic stroke patients with carotid atherosclerosis with those without according to the presence or the absence of carotid plaque defined by duplex scanning. METHODS: This was a case-control multi-center study that took place in one University hospital and two general hospitals in France. One hundred twenty-four symptomatic ischemic stroke patients (confirmation by a neurologist and imaging; 66% smokers) and 50 controls (34% smokers) without any known cardiovascular disease or previous nutritional advice were included. The main outcome measure(s) were intake scores for saturated (SFA), monounsaturated (MUFA), Omega-3 polyunsaturated (Omega-3 PUFA), and Omega-6 polyunsaturated fatty acids (Omega-6PUFA). Fruit and vegetables and an overall cardiovascular dietary score were evaluated with the FFQ. The overall cardiovascular score is calculated as (MUFA + Omega-3 PUFA + fruits and vegetables) - (SFA) scores. RESULTS: Compared with controls, ischemic stroke patients had a higher SFA score (6.6 +/- 3.0 vs 4.9 +/- 2.7; P < .001), lower scores of MUFA (0.8 +/- 0.9 vs 1.5 +/- 1.2; P < .001), Omega-3 PUFA (1.7 +/- 1.6 vs 2.2 +/- 1.5; P = .013), Omega-6PUFA (2.6 +/- 2.5 vs 3.9 +/- 2.7; P = .002), fruit and vegetables (2.9 +/- 1.7 vs 3.8 +/- 1.6; P = .005), and a lower overall dietary score (-1.2 +/- 5.0 vs 2.5 +/- 4.4; P < .001). These results remained statistically significant after adjustment for age, gender, and smoking status. Ischemic stroke patients with carotid atherosclerosis (n = 54) had a worse overall cardiovascular dietary score than those without (n = 68): -2.2 +/- 4.4 vs -0.2 +/- 5.2; P = .024. CONCLUSION: Compared with controls, ischemic stroke patients, especially those with carotid atherosclerosis, have an unfavorable dietary pattern (high SFA, low fruit and vegetables, and Omega-3 PUFA consumptions) that may have been a facilitating condition of the ischemic stroke. Dietary recommendations of a healthy diet should be useful in ischemic stroke prevention, especially in patients with cardiovascular risk factors.
Published: 2010
Full Text: View/download PDF

32. Optimization of high intensity interval exercise in coronary heart disease

Author: Mathieu Gayda, Martin Juneau, François Paillard, Said Mekary, Philippe Meyer, Thibaut Guiraud, Laurent Bosquet, and Anil Nigam
Subjects: Male, medicine.medical_specialty, Sports medicine, Physiology, Population, Physical Exertion, Physical exercise, Blood Pressure, Coronary Disease, Oxygen Consumption, Heart Rate, Physiology (medical), Internal medicine, Medicine, Humans, Orthopedics and Sports Medicine, Exercise physiology, education, Exercise, Aged, education.field_of_study, Exercise Tolerance, business.industry, Public Health, Environmental and Occupational Health, VO2 max, General Medicine, Recovery of Function, Middle Aged, Continuous training, Intensity (physics), Calibration, Cardiology, Physical therapy, Exercise Test, Physical Endurance, Female, business, human activities, High-intensity interval training
Abstract: High intensity interval training has been shown to be more effective than moderate intensity continuous training for improving maximal oxygen uptake (VO(2max)) in patients with coronary heart disease (CHD). However, no evidence supports the prescription of one specific protocol of high intensity interval exercise (HIIE) in this population. The purpose of this study was to compare the acute cardiopulmonary responses with four different single bouts of HIIE in order to identify the most optimal one in CHD patients. Nineteen stable CHD patients (17 males, 2 females, 65 +/- 8 years) performed four different bouts of HIIE, all with exercise phases at 100% of maximal aerobic power (MAP), but which varied in interval duration (15 s for mode A and B and 60 s for mode C and D) and type of recovery (0% of MAP for modes A and C and 50% of MAP for modes B and D). A passive recovery phase resulted in a longer time to exhaustion compared to an active recovery phase, irrespective of the duration of the exercise and recovery periods (15 or 60 s, p0.05). Time to exhaustion also tended to be higher with mode A relative to mode C (p = 0.06). Despite differences in time to exhaustion between modes, time spent at a high percentage of VO(2max) was similar between HIIE modes except for less time spent above 90 and 95% of VO(2max) for mode C when compared with modes B and D. When considering perceived exertion, patient comfort and time spent above 80% of VO(2max), mode A appeared to be the optimal HIIE session for these coronary patients.
Published: 2009

33. Plasma palmitoleic acid, a product of stearoyl-coA desaturase activity, is an independent marker of triglyceridemia and abdominal adiposity

Author: Philippe Legrand, Franck Le Duff, Jean-Claude Daubert, Daniel Catheline, Michel Pouchard, François Paillard, Monique Bouriel, Yves Deugnier, Laboratoire de Biochimie et Nutrition Humaine, AGROCAMPUS OUEST, and Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)-Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)
Subjects: Male, Endocrinology, Diabetes and Metabolism, Medicine (miscellaneous), middle-aged men, cardiovascular-disease, MESH: Logistic Models, Body Mass Index, Fatty Acids, Monounsaturated, chemistry.chemical_compound, Waist–hip ratio, MESH: Cholesterol, Palmitoleic acid, MESH: Obesity, MESH: Hypertriglyceridemia, risk-factors, triglycerides, Hypertriglyceridemia, chemistry.chemical_classification, MESH: Aged, Nutrition and Dietetics, MESH: Middle Aged, Anthropometry, MESH: Waist-Hip Ratio, Middle Aged, [SDV.BBM.BC]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Biomolecules [q-bio.BM], Stearoyl-CoA Desaturase, MESH: Fatty Acids, Monounsaturated, Body Composition, acid, insulin-resistance syndrome, Cardiology and Cardiovascular Medicine, Adult, MESH: Triglycerides, medicine.medical_specialty, abdominal adiposity, Abdominal Fat, diabetic mice, metabolic syndrome, MESH: Multivariate Analysis, MESH: Abdominal Fat, MESH: Body Mass Index, ob-ob, MESH: Anthropometry, Internal medicine, medicine, Humans, Obesity, palmitoleic, stearoyl-coA, Aged, MESH: Humans, Waist-Hip Ratio, business.industry, Cholesterol, MESH: Biological Markers, cholesterol, tissue, MESH: Adult, Stearoyl-CoA, MESH: Body Composition, medicine.disease, gene-expression, MESH: Male, Logistic Models, Endocrinology, Enzyme, chemistry, Multivariate Analysis, MESH: Stearoyl-CoA Desaturase, Metabolic syndrome, business, Body mass index, desaturase, Biomarkers
Abstract: BACKGROUND AND AIM: In an animal model VLDL-triglyceride secretion is highly dependent on stearoyl-coA desaturase (SCD) activity and could explain abdominal fattening. The aim was to assess the relationship of plasma palmitoleic acid content, a product of SCD activity, with triglyceridemia and abdominal adiposity in humans. METHODS: We evaluated 134 healthy men. Plasma palmitoleic acid content was used as an indirect measurement of SCD activity because that enzyme catalyzes the desaturation from saturated to monounsaturated fatty acids and palmitoleic acid intake is very small. RESULTS: Subjects with triglycerides > or =75th percentile had a higher palmitoleic acid content than those with triglycerides
Published: 2008
Full Text: View/download PDF

34. Relative validity and reproducibility of a 14-item semi-quantitative food frequency questionnaire for cardiovascular prevention

Author: Pascal Guillo, Christèle Froger-Bompas, Anne Sevestre, Michel Pouchard, Bruno Laviolle, Catherine Letellier, Jean-Claude Daubert, and François Paillard
Subjects: Adult, Male, Pathology, medicine.medical_specialty, Time Factors, Epidemiology, Cardiovascular prevention, Environmental health, Surveys and Questionnaires, medicine, Humans, Aged, Reproducibility, Nutrition assessment, business.industry, Food frequency questionnaire, Reproducibility of Results, Feeding Behavior, Middle Aged, Clinical Practice, Cardiovascular Diseases, Food, Disease risk, Female, Cardiology and Cardiovascular Medicine, business, Semi quantitative, Relative validity, Follow-Up Studies
Abstract: Dietary habits play a major role in cardiovascular disease risk but few simple nutrition assessment tools are available for clinical practice. We developed a 14-item food frequency questionnaire to evaluate dietary patterns in relation with coronary risk in a French population.This food frequency questionnaire gave different scores of intake: saturated fatty acids (six questions), mono-unsaturated fatty acids, Omega-3 and Omega-6/Omega-3 polyunsaturated fatty acids (five questions), and fruits and vegetables (three questions). Validity was assessed against a 7-day dietary history (n = 49 subjects) and against biomarkers (n = 181). The food frequency questionnaire was also administered twice with an interval of 15 days to evaluate its reproducibility (n = 20).Validity against dietary history was assessed with Spearman correlation coefficients which ranged from 0.47 (fruits and vegetables) to 0.63 (polyunsaturated fatty acids/saturated fatty acids) (all P0.05), with a mean value of 0.54. On average, 39% of the subjects were classified in the same quartile with the food frequency questionnaire and the dietary history and 84% in the same or adjacent quartile. Biomarker-based validity using Spearman correlation coefficients varied from 0.21 (saturated fatty acids) to 0.53 (Omega-3 polyunsaturated fatty acids) (all P0.05), with a mean value of 0.35. On average, 37% of the participants were classified in the same quartile with the food frequency questionnaire and the corresponding biomarkers and 73% in the same or adjacent quartile. Reproducibility assessed by the intraclass correlation coefficient ranged from 0.71 (mono-unsaturated fatty acids) to 0.93 (global score), with a mean value of 0.81.We validated a short food frequency questionnaire for dietary pattern assessment in coronary prevention.
Published: 2005

35. Rôle de la Δ9 désaturase dans l’hypertriglycéridémie et l’adiposité chez l’homme

Author: Monique Bouriel, Jean-Claude Daubert, F. Le Duff, Philippe Legrand, François Paillard, and Daniel Catheline
Subjects: Nutrition and Dietetics, Medicine (miscellaneous)
Published: 2004
Full Text: View/download PDF

36. Effect of an Educational Program (PEGASE) on Cardiovascular Risk in Hypercholesterolaemic Patients.

Author: Eric Bruckert, Philippe Giral, François Paillard, Jean Ferrières, Jean-Louis Schlienger, Jean-François Renucci, Kamel Abdennbi, Isabelle Durack, and Rita Chadarevian
Abstract: Abstract Background Many studies have demonstrated a gap between guidelines for the prevention of cardiovascular disease (CVD) and their implementation in clinical practice. Aim The PEGASE education program has been devised with an aim to improve the management of patients at high risk of CVD. Methods In a multicentre study carried out from 2001–2004 in France, 96 participating physicians were randomized into a “trained” group, which included 398 “educated” patients, and a “non-trained” group, which included 242 “non-educated” patients. Educated patients received six hospital-based educational sessions, four collective and two individual. Framingham score, smoking, lipid levels, glycaemia, blood pressure, dietary intake and drug compliance, as well as quality of life, were evaluated at baseline (M0) and 6 months (M6). The primary endpoint of the study was the efficacy of the PEGASE program in reducing global CVD risk in high-risk patients. Results The Framingham score was calculated for 473 patients. The Framingham score improved significantly at M6 vs M0 in the educated group (13.0 ± 8.21 vs 13.6 ± 8.48, d = −0.658, p = 0.016), but not in the non-educated group (12.5 ± 8.19 vs 12.4 ± 7.81, d = +0.064, p = 0.836); the mean change between the two groups did not reach significance. Quality of life, LDL-c level and diet scores improved in the “educated” group only. Conclusions The PEGASE education program improved risk factors for CVD, although global assessment by Framingham score was not significantly different between groups. This program, aimed at meeting needs and expectations of patients and physicians, was easily implemented in all hospital centres. [ABSTRACT FROM AUTHOR]
Published: 2008

37. MESSE DE MINUIT / M.A. CHARPENTIER

Author: Lambert, Guy (1906-1971). Transcripteur. Réalisateur, Charpentier, Marc Antoine (1643-1704). Auteur ou responsable intellectuel, Selig, Edith (1929-2020). Soprano, Meurant, André. Contre-ténor, Martini, Louis (1912-2000). Direction d'orchestre, Lesueur, Jean-Jacques. Ténor, Duruflé, Maurice (1902-1986). Orgue, Beckensteiner, Anne-Marie. Orgue, Angelici, Martha (1907-1973). Soprano, Abdoun, Georges. Baryton (voix), Orchestre de chambre Jean-François Paillard. Interprète, Chorale des Jeunesses Musicales de France. Interprète, Lambert, Guy (1906-1971). Transcripteur. Réalisateur, Charpentier, Marc Antoine (1643-1704). Auteur ou responsable intellectuel, Selig, Edith (1929-2020). Soprano, Meurant, André. Contre-ténor, Martini, Louis (1912-2000). Direction d'orchestre, Lesueur, Jean-Jacques. Ténor, Duruflé, Maurice (1902-1986). Orgue, Beckensteiner, Anne-Marie. Orgue, Angelici, Martha (1907-1973). Soprano, Abdoun, Georges. Baryton (voix), Orchestre de chambre Jean-François Paillard. Interprète, and Chorale des Jeunesses Musicales de France. Interprète
Abstract: BnF-Partenariats, Collection sonore - Believe, Contient une table des matières
Published: 1962

38. Les concertos pour clavecin et orchestre : choix / J. S. Bach, comp. ; Robert Veyron-Lacroix, Anne-Marie Beckensteiner, Marie-Claire Alain, Olivier Alain, clav. ; Orchestre de Chambre de Jean-François Paillard

Author: Bach, Johann Sebastian (1685-1750). Compositeur, Veyron-Lacroix, Robert (1922-1991). Clavecin, Paillard, Jean-François (1928-2013). Direction d'orchestre, Beckensteiner, Anne-Marie. Clavecin, Alain, Olivier (1918-1994). Clavecin, Alain, Marie-Claire (1926-2013). Orgue, Orchestre de chambre Jean-François Paillard. Orchestre, Bach, Johann Sebastian (1685-1750). Compositeur, Veyron-Lacroix, Robert (1922-1991). Clavecin, Paillard, Jean-François (1928-2013). Direction d'orchestre, Beckensteiner, Anne-Marie. Clavecin, Alain, Olivier (1918-1994). Clavecin, Alain, Marie-Claire (1926-2013). Orgue, and Orchestre de chambre Jean-François Paillard. Orchestre
Abstract: Titre uniforme : Bach, Johann Sebastian (1685-1750). Compositeur. [Concertos. BWV 1041-1065]. Choix, BnF-Partenariats, Collection sonore - Believe, Contient une table des matières
Published: 1960

39. Concerto pour flûte et harpe KV 299 / Mozart, comp. ; Jean-Pierre Rampal, fl. ; Lily Laskine, hrp ; Orchestre de chambre de Jean-François Paillard ; Jean-François Paillard, dir.. Concerto pour clarinette en la majeur KV 622 / Mozart, comp. ; Jacques Lancelot, clar. ; Orchestre de chambre de Jean-François Paillard ; Jean-François Paillard, dir.

Author: Mozart, Wolfgang Amadeus (1756-1791). Compositeur, Paillard, Jean-François (1928-2013). Direction d'orchestre, Rampal, Jean-Pierre (1922-2000). Flûte, Laskine, Lily (1893-1988). Harpe, Lancelot, Jacques (1920-2009). Clarinette, Orchestre de chambre Jean-François Paillard. Ensemble instrumental, Mozart, Wolfgang Amadeus (1756-1791). Compositeur, Paillard, Jean-François (1928-2013). Direction d'orchestre, Rampal, Jean-Pierre (1922-2000). Flûte, Laskine, Lily (1893-1988). Harpe, Lancelot, Jacques (1920-2009). Clarinette, and Orchestre de chambre Jean-François Paillard. Ensemble instrumental
Abstract: Titre uniforme : Mozart, Wolfgang Amadeus (1756-1791). Compositeur. [Concertos. Flûte, harpe, orchestre. KV 297c. Do majeur], Titre uniforme : Mozart, Wolfgang Amadeus (1756-1791). Compositeur. [Concertos. Clarinette, orchestre. KV 622. La majeur], Comprend : Concerto pour flûte et harpe KV 299 ; Concerto pour clarinette en la majeur KV 622, BnF-Partenariats, Collection sonore - Believe, Contient une table des matières
Published: 1960

40. Les concertos pour clavecin et orchestre. Volume 4 / J. S. Bach, comp. ; Robert Veyron-Lacroix, Anne-Marie Beckensteiner, Marie-Claire Alain, Olivier Alain, clav. ; Orchestre de Chambre de Jean-François Paillard

Author: Bach, Johann Sebastian (1685-1750). Compositeur, Veyron-Lacroix, Robert (1922-1991). Clavecin, Paillard, Jean-François (1928-2013). Direction d'orchestre, Beckensteiner, Anne-Marie. Clavecin, Alain, Olivier (1918-1994). Clavecin, Alain, Marie-Claire (1926-2013). Orgue, Orchestre de chambre Jean-François Paillard. Orchestre, Bach, Johann Sebastian (1685-1750). Compositeur, Veyron-Lacroix, Robert (1922-1991). Clavecin, Paillard, Jean-François (1928-2013). Direction d'orchestre, Beckensteiner, Anne-Marie. Clavecin, Alain, Olivier (1918-1994). Clavecin, Alain, Marie-Claire (1926-2013). Orgue, and Orchestre de chambre Jean-François Paillard. Orchestre
Abstract: Titre uniforme : Bach, Johann Sebastian (1685-1750). Compositeur. [Concertos. Claviers (4), orchestre à cordes, basse continue. BWV 1065. La mineur], Titre uniforme : Bach, Johann Sebastian (1685-1750). Compositeur. [Concertos. Claviers (3), orchestre à cordes, basse continue. BWV 1064. Do majeur], Titre uniforme : Bach, Johann Sebastian (1685-1750). Compositeur. [Concertos. Claviers (3), orchestre à cordes, basse continue. BWV 1063. Ré mineur], Comprend : Concerto pour 4 clavecins en la mineur, BWV 1065 - Concerto pour 3 clavecins en ré mineur, BWV 1063 - Concerto pour 3 clavecins en do majeur, BWV 1064, BnF-Partenariats, Collection sonore - Believe, Contient une table des matières
Published: 1960

41. Les concertos pour clavecin et orchestre. Volume 2 / J. S. Bach, comp. ; Robert Veyron-Lacroix, clav ; Orchestre de Chambre de Jean-François Paillard

Author: Bach, Johann Sebastian (1685-1750). Compositeur, Veyron-Lacroix, Robert (1922-1991). Clavecin, Paillard, Jean-François (1928-2013). Direction d'orchestre, Orchestre de chambre Jean-François Paillard. Orchestre, Bach, Johann Sebastian (1685-1750). Compositeur, Veyron-Lacroix, Robert (1922-1991). Clavecin, Paillard, Jean-François (1928-2013). Direction d'orchestre, and Orchestre de chambre Jean-François Paillard. Orchestre
Abstract: Titre uniforme : Bach, Johann Sebastian (1685-1750). Compositeur. [Concertos. Clavier, orchestre à cordes, basse continue. BWV 1055. La majeur], Titre uniforme : Bach, Johann Sebastian (1685-1750). Compositeur. [Concertos. Clavier, orchestre à cordes, basse continue. BWV 1058. Sol mineur], Titre uniforme : Bach, Johann Sebastian (1685-1750). Compositeur. [Concertos. Clavier, orchestre à cordes, basse continue. BWV 1053. Mi majeur], Comprend : Concerto pour clavecin et orchestre en la majeur, BWV 1055 - Concerto pour clavecin et orchestre en mi majeur, BWV 1053 - Concerto pour clavecin et orchestre en sol mineur, BWV 1058, BnF-Partenariats, Collection sonore - Believe, Contient une table des matières
Published: 1960

42. DANSES SACREE ET PROFANE ; 3 SONATES / CLAUDE DEBUSSY ; ORCHESTRE DE CHAMBRE J.F. PAILLARD

Author: Debussy, Claude (1862-1918). Auteur ou responsable intellectuel, Tortelier, Paul (1914-1990). Violoncelle, Rampal, Jean-Pierre (1922-2000). Direction d'orchestre, Rampal, Jean-Pierre (1922-2000). Flûte, Pasquier, Pierre (1902-1986). Violon, Laskine, Lily (1893-1988). Harpe, Hubeau, Jean (1917-1992). Piano, Cyroulnik, Charles (1923-2003). Violon, Orchestre de chambre Jean-François Paillard. Interprète, Debussy, Claude (1862-1918). Auteur ou responsable intellectuel, Tortelier, Paul (1914-1990). Violoncelle, Rampal, Jean-Pierre (1922-2000). Direction d'orchestre, Rampal, Jean-Pierre (1922-2000). Flûte, Pasquier, Pierre (1902-1986). Violon, Laskine, Lily (1893-1988). Harpe, Hubeau, Jean (1917-1992). Piano, Cyroulnik, Charles (1923-2003). Violon, and Orchestre de chambre Jean-François Paillard. Interprète
Abstract: Titre uniforme : [Sonates. Violon, piano. FL 148. Sol mineur], Titre uniforme : [Sonate en trio. Flûte, harpe, alto. FL 145], Titre uniforme : [Sonates. Violoncelle, piano. FL 144. Ré mineur], Titre uniforme : [2 danses. Harpe, orchestre à cordes. FL 113], BnF-Partenariats, Collection sonore - Believe, Contient une table des matières
Published: 1962

43. Danses sacrée et profane / Debussy, comp. ; Lily Laskine, harpe ; Orchestre de chambre Jean-François Paillard ; Jean-Pierre Rampal, dir.. Sonate pour flûte, alto et harpe / Debussy, comp. ; Lily Laskine, hrp ; Jean-Pierre Rampal, fl. ; Pierre Pasquier, alto. Sonate pour violoncelle et piano... [etc.] / Debussy, comp. ; Paul Tortelier, vlc ; Jean Hubeau, p

Author: Debussy, Claude (1862-1918). Compositeur, Laskine, Lily (1893-1988). Harpe, Rampal, Jean-Pierre (1922-2000). Direction d'orchestre, Rampal, Jean-Pierre (1922-2000). Flûte, Pasquier, Pierre (1902-1986). Violon, Tortelier, Paul (1914-1990). Violoncelle, Hubeau, Jean (1917-1992). Piano, Cyroulnik, Charles (1923-2003). Violon, Orchestre de chambre Jean-François Paillard. Interprète, Debussy, Claude (1862-1918). Compositeur, Laskine, Lily (1893-1988). Harpe, Rampal, Jean-Pierre (1922-2000). Direction d'orchestre, Rampal, Jean-Pierre (1922-2000). Flûte, Pasquier, Pierre (1902-1986). Violon, Tortelier, Paul (1914-1990). Violoncelle, Hubeau, Jean (1917-1992). Piano, Cyroulnik, Charles (1923-2003). Violon, and Orchestre de chambre Jean-François Paillard. Interprète
Abstract: Titre uniforme : Debussy, Claude (1862-1918). Compositeur. [2 danses. Harpe, orchestre à cordes. FL 113], Titre uniforme : Debussy, Claude (1862-1918). Compositeur. [Sonate en trio. Flûte, harpe, alto. FL 145], Titre uniforme : Debussy, Claude (1862-1918). Compositeur. [Sonates. Violoncelle, piano. FL 144. Ré mineur], Titre uniforme : Debussy, Claude (1862-1918). Compositeur. [Sonates. Violon, piano. FL 148. Sol mineur], Comprend : Danses sacrée et profane / Debussy, comp. ; Lily Laskine, hrp ; Orchestre de chambre Jean-François Paillard ; Jean-Pierre Rampal, dir. ; Sonate pour flûte, alto et harpe / Debussy, comp. ; Lily Laskine, hrp ; Jean-Pierre Rampal, fl. ; Pierre Pasquier, alto ; Sonate pour violoncelle et piano / Debussy, comp. ; Paul Tortelier, vlc ; Jean Hubeau, p ; Sonate pour violon et piano / Debussy, comp. ; Charles Cyroulnik, vl ; Jean Hubeau, p, BnF-Partenariats, Collection sonore - Believe, Contient une table des matières
Published: 1962

44. WATER MUSIC - version originale / Georg-Friedrich HAENDEL ; l'Orchestre de Chambre Jean-François PAILLARD

Author: Händel, Georg Friedrich (1685-1759). Auteur ou responsable intellectuel, Paillard, Jean-François (1928-2013). Direction d'orchestre, Orchestre de chambre Jean-François Paillard. Interprète, Händel, Georg Friedrich (1685-1759). Auteur ou responsable intellectuel, Paillard, Jean-François (1928-2013). Direction d'orchestre, and Orchestre de chambre Jean-François Paillard. Interprète
Abstract: Titre uniforme : [Water music. Orchestre. HWV 348-350]. Intégrale, BnF-Partenariats, Collection sonore - Believe, Contient une table des matières
Published: 1960

45. 13 DANSES ALLEMANDES : KV 602, 605, 600 / W.A. MOZART ; l'ORCHESTRE DE CHAMBRE JEAN-FRANCOIS PAILLARD

Author: Mozart, Wolfgang Amadeus (1756-1791). Compositeur, Paillard, Jean-François (1928-2013). Direction d'orchestre, Orchestre de chambre Jean-François Paillard. Orchestre, Mozart, Wolfgang Amadeus (1756-1791). Compositeur, Paillard, Jean-François (1928-2013). Direction d'orchestre, and Orchestre de chambre Jean-François Paillard. Orchestre
Abstract: Titre uniforme : Mozart, Wolfgang Amadeus (1756-1791). Compositeur. [Vier deutsche Tänze. KV 602], Titre uniforme : Mozart, Wolfgang Amadeus (1756-1791). Compositeur. [Drei deutsche Tänze. KV 605], Titre uniforme : Mozart, Wolfgang Amadeus (1756-1791). Compositeur. [Sechs deutsche Tänze. Orchestre. KV 600], Collection : Fiori musicali, Comprend : 4 DANSES ALLEMANDES : KV 602 - 3 DANSES ALLEMANDES : KV 605 - 6 DANSES ALLEMANDES : KV 600, BnF-Partenariats, Collection sonore - Believe, Contient une table des matières
Published: 1962

46. MUSIQUE VOCALE FRANCAISE DE LULLI A RAMEAU / Edith SELIG, soprano - Jacques VILLISECH, basse - Chorale Philippe CAILLARD et Orchestre de Chambre Jean-François PAILLARD dir. JEAN-François PAILLARD

Author: Rameau, Jean-Philippe (1683-1764). Auteur ou responsable intellectuel, Lully, Jean-Baptiste (1632-1687). Auteur ou responsable intellectuel, Leclair, Jean-Marie (1697-1764). Auteur ou responsable intellectuel, Lalande, Michel Richard de (1657-1726). Auteur ou responsable intellectuel, Destouches, André Cardinal (1672-1749). Auteur ou responsable intellectuel, Couperin, François (1668-1733). Auteur ou responsable intellectuel, Clérambault, Nicolas (1676-1749). Auteur ou responsable intellectuel, Campra, André (1660-1744). Auteur ou responsable intellectuel, Villisech, Jacques. Basse (voix), Selig, Edith (1929-2020). Soprano, Paillard, Jean-François (1928-2013). Direction d'orchestre, Orchestre de chambre Jean-François Paillard. Interprète, Chorale Philippe Caillard. Interprète, Rameau, Jean-Philippe (1683-1764). Auteur ou responsable intellectuel, Lully, Jean-Baptiste (1632-1687). Auteur ou responsable intellectuel, Leclair, Jean-Marie (1697-1764). Auteur ou responsable intellectuel, Lalande, Michel Richard de (1657-1726). Auteur ou responsable intellectuel, Destouches, André Cardinal (1672-1749). Auteur ou responsable intellectuel, Couperin, François (1668-1733). Auteur ou responsable intellectuel, Clérambault, Nicolas (1676-1749). Auteur ou responsable intellectuel, Campra, André (1660-1744). Auteur ou responsable intellectuel, Villisech, Jacques. Basse (voix), Selig, Edith (1929-2020). Soprano, Paillard, Jean-François (1928-2013). Direction d'orchestre, Orchestre de chambre Jean-François Paillard. Interprète, and Chorale Philippe Caillard. Interprète
Abstract: Titre uniforme : [Les Indes galantes. RCT 44]. Extrait, Titre uniforme : [Thésée. LWV 51]. Extrait, Titre uniforme : [Épitaphe d'un paresseux], Comprend : Air de "Thésée" : "Revenez, amours" / J.B. LULLI (soprano, deux violons et basse continue) - EPITAPHE D'UN PARESSEUX / François COUPERIN (soprano, basse et basse continue) - Air d'"Orphée" : "Laissez-vous toucher..." / L.N. CLERAMBAULT (basse, flûte, violon et basse continue) - Air du "Carnaval de Venise" : "Orfeo nell inferi" / A. CAMPRA (soprano, violon et basse continue) - PASSACAILLE DE SCYLLA ET GLAUCUS / Jean-Marie LECLAIR (Soprano, choeurs et orchestre) - LES ELEMENTS / DESTOUCHES et DELALANDE (duo - Choeur et orchestre) - SILENE : "Air" (basse, violon et basse continue) - La Farfalla : Air extrait des "FETES VENITIENNES" / A. CAMPRA (soprano, flûte, violon et basse continue) - MUSETTE / François COUPERIN (soprano, basse et basse continue) - AIR : extrait de "LE BERGER FIDELE" (cantate) (soprano, deux violons et basse continue) - Air des "INDES GALANTES" : "Brillant soleil" (basse, choeurs et orchestre) / Jean-Philippe RAMEAU, BnF-Partenariats, Collection sonore - Believe, Contient une table des matières
Published: 1961

47. Les concertos pour clavecin et orchestre. Volume 1 / J. S. Bach, comp. ; Robert Veyron-Lacroix, clav ; Orchestre de Chambre de Jean-François Paillard

Author: Bach, Johann Sebastian (1685-1750). Compositeur, Veyron-Lacroix, Robert (1922-1991). Clavecin, Paillard, Jean-François (1928-2013). Direction d'orchestre, Orchestre de chambre Jean-François Paillard. Orchestre, Bach, Johann Sebastian (1685-1750). Compositeur, Veyron-Lacroix, Robert (1922-1991). Clavecin, Paillard, Jean-François (1928-2013). Direction d'orchestre, and Orchestre de chambre Jean-François Paillard. Orchestre
Abstract: Titre uniforme : Bach, Johann Sebastian (1685-1750). Compositeur. [Concertos. Clavier, orchestre à cordes, basse continue. BWV 1052. Ré mineur], Titre uniforme : Bach, Johann Sebastian (1685-1750). Compositeur. [Concertos. Clavier, orchestre à cordes, basse continue. BWV 1056. Fa mineur], Titre uniforme : Bach, Johann Sebastian (1685-1750). Compositeur. [Concertos. Clavier, orchestre à cordes, basse continue. BWV 1054. Ré majeur], Comprend : Concerto pour clavecin et orchestre en ré mineur, BWV 1052 - Concerto pour clavecin et orchestre en fa mineur, BWV 1056 - Concerto pour clavecin et orchestre en ré majeur, BWV 1054, BnF-Partenariats, Collection sonore - Believe, Contient une table des matières
Published: 1960

48. FANFARES POUR DES TROMPETTES, TIMBALES, VIOLONS ET HAUTBOIS ; SIMPHONIES POUR DES VIOLONS ET HAUTBOIS ET DES CORS DE CHASSE : Seconde Suite / Jean-Joseph MOURET. SUITE DE SIMPHONIES D'AMADIS / Jean-Baptiste LULLY. SUITE FRANÇAISE EN SOL MINEUR / un disciple anonyme de LULLY mise en partition par Mr BARRE ; l'Orchestre de Chambre Jean-François PAILLARD dir. Jean-François PAILLARD

Author: Mouret, Jean-Joseph (1682-1738). Auteur ou responsable intellectuel, Lully, Jean-Baptiste (1632-1687). Auteur ou responsable intellectuel, Paillard, Jean-François (1928-2013). Direction d'orchestre, Orchestre de chambre Jean-François Paillard. Interprète, Mouret, Jean-Joseph (1682-1738). Auteur ou responsable intellectuel, Lully, Jean-Baptiste (1632-1687). Auteur ou responsable intellectuel, Paillard, Jean-François (1928-2013). Direction d'orchestre, and Orchestre de chambre Jean-François Paillard. Interprète
Abstract: Titre uniforme : [Amadis. LWV 63], BnF-Partenariats, Collection sonore - Believe, Contient une table des matières
Published: 1961

49. FANFARES - SIMPHONIES ET SUITES / l'Orchestre de Chambre Jean-François PAILLARD dir. Jean-François PAILLARD

Author: Mouret, Jean-Joseph (1682-1738). Auteur ou responsable intellectuel, Lully, Jean-Baptiste (1632-1687). Auteur ou responsable intellectuel, Paillard, Jean-François (1928-2013). Direction d'orchestre, Orchestre de chambre Jean-François Paillard. Interprète, Mouret, Jean-Joseph (1682-1738). Auteur ou responsable intellectuel, Lully, Jean-Baptiste (1632-1687). Auteur ou responsable intellectuel, Paillard, Jean-François (1928-2013). Direction d'orchestre, and Orchestre de chambre Jean-François Paillard. Interprète
Abstract: Titre uniforme : [Amadis. LWV 63], Comprend : FANFARES POUR DES TROMPETTES, TIMBALES, VIOLONS ET HAUTBOIS / Jean-Joseph MOURET - SIMPHONIES POUR DES VIOLONS ET HAUTBOIS ET DES CORS DE CHASSE : seconde suite / Jean-Joseph MOURET - SUITE DE SIMPHONIES D'AMADIS / Jean-Baptiste LULLY - SUITE FRANCAISE EN SOL MINEUR / mise en partition par M. BARRE d'un disciple anonyme de LULLY, BnF-Partenariats, Collection sonore - Believe, Contient une table des matières
Published: 1961

50. TE DEUM POUR SOLI CHOEUR ET ORCHESTRE / DE LALANDE

Author: Lalande, Michel Richard de (1657-1726). Auteur ou responsable intellectuel, Selig, Edith (1929-2020). Soprano, Meurant, André. Contre-ténor, Martini, Louis (1912-2000). Direction d'orchestre, Lesueur, Jean-Jacques. Ténor, Angelici, Martha (1907-1973). Soprano, Alain, Marie-Claire (1926-2013). Orgue, Abdoun, Georges. Baryton (voix), Orchestre de chambre Jean-François Paillard. Interprète, Chorale des Jeunesses Musicales de France. Interprète, Lalande, Michel Richard de (1657-1726). Auteur ou responsable intellectuel, Selig, Edith (1929-2020). Soprano, Meurant, André. Contre-ténor, Martini, Louis (1912-2000). Direction d'orchestre, Lesueur, Jean-Jacques. Ténor, Angelici, Martha (1907-1973). Soprano, Alain, Marie-Claire (1926-2013). Orgue, Abdoun, Georges. Baryton (voix), Orchestre de chambre Jean-François Paillard. Interprète, and Chorale des Jeunesses Musicales de France. Interprète
Abstract: Titre uniforme : [Te Deum. Voix (6), choeur à 5 voix, orchestre. S 32], BnF-Partenariats, Collection sonore - Believe, Contient une table des matières
Published: 1961

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Database

Publisher

85 results on '"François Paillard"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources